197 results on '"Bhaskar N"'
Search Results
2. Role of Amputation in Improving Mobility, Pain Outcomes, and Emotional and Psychological Well-Being in Children With Metastatic Osteosarcoma
- Author
-
Sebastian Gil, Justin N. Baker, Jianrong Wu, Bhaskar N. Rao, Israel Fernandez-Pineda, Michael D. Neel, Huiyun Wu, and Doralina L. Anghelescu
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,General Medicine ,Limb amputation ,03 medical and health sciences ,0302 clinical medicine ,Amputation ,030502 gerontology ,030220 oncology & carcinogenesis ,Psychological well-being ,Metastatic osteosarcoma ,medicine ,Physical therapy ,0305 other medical science ,business - Abstract
Background: Few studies have analyzed the benefit of limb amputations in children with metastatic osteosarcoma and limited life span. Objective: We studied outcomes of limb amputations in children with metastatic osteosarcoma. Design: We performed a retrospective review of patients who underwent limb amputations (January 1995-June 2015) and died within 1 year of surgery. Setting/Participants: We studied 12 patients with osteosarcoma at a single institution. Measurements: Data on mobility, pain, and emotional and psychological well-being were retrieved from medical records from 1 month before surgery to 6 months after surgery. Results: Of the 12 patients (7 females and 5 males; median age at surgery 13 years [range, 7-20 years]) meeting study criteria, 3 patients and 9 patients had primary osteosarcoma in upper and lower limbs, respectively. Mobility improved postamputation in 8 bedridden/wheelchair-bound patients. Postamputation, emotional, and psychological well-being improved for 9 patients, 3 patients had persistent psychological and/or emotional symptoms, and no patient experienced signs of regret. Daily mean pain scores were significantly lower at 1 week (median 3 [range, 0-6]; P = .03) and 3 months (median 0 [range, 0-8]; P = .02) postsurgery than at 1 week presurgery (median 5.5 [range, 0-10]). Morphine consumption (mg/kg/d) showed a trend toward higher values at 1 week (median 0.2 [range, 0-7.6]; P = .6) and 3 months (median 0.2 [range, 0-0.5]; P = .3) postsurgery than at 1 week presurgery (median 0.1 [range, 0-0.5]). Conclusions: Patients undergoing limb amputations had reduced pain and improved mobility and emotional and psychological well-being. Amputations are likely to benefit children with limited life expectancy.
- Published
- 2018
3. Extremity bone sarcoma: Evolution from primary amputation to limb salvage surgery (LSS)
- Author
-
Hafeez Abdelhafeez, Sandra Murphy, Michael D. Neel, and Bhaskar N. Rao
- Subjects
Cancer Research ,Chemotherapy ,Limb salvage surgery ,medicine.medical_specialty ,Oncology ,Amputation ,business.industry ,medicine.medical_treatment ,Medicine ,Bone Sarcoma ,business ,Surgery - Abstract
e22012 Background: Primary Extremity Bone Sarcomas (PEBS) were historically managed by upfront amputation. Early success rates utilizing neoadjuvant chemotherapy followed by LSS showed promise in halting disease progression and achieving local control. This prompted surgical oncologists to consider LSS in more patients. In anatomic locations for which no functional reconstruction exists, amputation is still considered the best option. Oncologic control, patient satisfaction and improved function are the primary goals of LSS. Three Dimensional CT and MRI have made for more accurate surgical planning, ensuring adequate margins and improved local control. Methods: Between January 1983 and December 2019 the senior author (BNR) has performed, or mentored over 590 LSS worldwide.Improvement in imaging modalities has been the most important advancement contributing to decreasing tumor margins. Initially bone scans determined the margins at 7cm. In the 1970s CT became the modality used to determine local tumor extent. The resection margins were reduced to 5 cm. The early 90’s saw MRI as the main imaging modality. Margins are now set at 1-2cm.LSS was initiated in the mid 80’s using the strict criteria of age > 13, no metastasis, intramedullary extension less than 50%, and small extraosseus extent. Results: Of the 134 cases enrolled through 1990, the local control rate was 90%. Between July 1991 through December 2019, 388 patients enrolled in bone sarcoma protocols, 354 patients underwent LSS ( > 95%). The primary site was the femur (171 cases, 43%) Histological Diagnosis was OS in 93%. Ages ranged from 3-25 years (median 10.8 years) The average length of tumor resection was 7cms(range 1-38cms). 5 patients presented with pathological fracture. All successfully underwent LSS without an increase in local recurrence. Intraoperative complications included, excessive hemorrhage defined as > 10%of blood volume in 88 patients, 25%, Vascular injuries requiring repair in 9 patients, post operative neuropraxia in 28 patients. Mid and late term complications included, Superficial wound infection in 45 patients (19 requiring some surgical intervention), Deep wound problems were identified in 11 patients ( 3 required subsequent amputation), 9 patients had their prosthesis revised due to refractory infection, Local relapse in 5 patients , < 1%. Long term implant related complications, loosening of the prosthesis in 16 , Stem fracture in 13, nonunion of the allograft in 3 patients. Conclusions: Disadvantages are the need for repeat surgeries consequent to either growth discrepancy, loosening, or implant fracture.LSS is feasible in over 95% of patients, complications are generally manageable. Successful oncologic results, satisfaction and function are readily obtained. Early rehabilitation is key to functional success.
- Published
- 2021
4. Associations between treatment, scoliosis, pulmonary function, and physical performance in long-term survivors of sarcoma
- Author
-
William C. Warner, Andrew M. Davidoff, Bhaskar N. Rao, Kirsten K. Ness, Daniel M. Green, Chenghong Li, Israel Fernandez-Pineda, Leslie L. Robison, Rodrigo B. Interiano, Matthew J. Krasin, Sue C. Kaste, Deo Kumar Srivastava, and Melissa M. Hudson
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Scoliosis ,Article ,Pulmonary function testing ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Surveys and Questionnaires ,medicine ,Humans ,Survivors ,030212 general & internal medicine ,Thoracotomy ,Child ,Lung ,Oncology (nursing) ,business.industry ,Incidence ,Incidence (epidemiology) ,Infant ,Sarcoma ,Middle Aged ,medicine.disease ,Rib resection ,Confidence interval ,Respiratory Function Tests ,Surgery ,Oncology ,Child, Preschool ,030220 oncology & carcinogenesis ,Relative risk ,Chronic Disease ,Female ,Self Report ,business - Abstract
Longer survival for children with sarcoma has led to the recognition of chronic health conditions related to prior therapy. We sought to study the association of sarcoma therapy with the development of scoliosis. We reviewed patient demographics, treatment exposures, and functional outcomes for patients surviving >10 years after treatment for sarcoma between 1964 and 2002 at our institution. The diagnosis of scoliosis was determined by imaging. Functional performance and standardized questionnaires were completed in a long-term follow-up clinic. We identified 367 patients, with median age at follow-up of 33.1 years. Scoliosis was identified in 100 (27.2%) patients. Chest radiation (relative risk (RR), 1.88 (95% confidence interval (CI), 1.21–2.92), p
- Published
- 2017
5. Feasibility and Functional Outcomes of Children and Adolescents Undergoing Preoperative Chemotherapy Prior to a Limb-Sparing Procedure or Amputation
- Author
-
Michael W. Bishop, Alberto S. Pappo, Michael D. Neel, Wei Liu, Angela Meyer Corr, Deo Kumar Srivastava, Terry Wilson, Kirsten K. Ness, and Bhaskar N. Rao
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,education.educational_degree ,Physical Therapy, Sports Therapy and Rehabilitation ,Malignancy ,Article ,Habilitation ,03 medical and health sciences ,0302 clinical medicine ,Medicine ,Generalizability theory ,education ,Oncology (nursing) ,business.industry ,Rehabilitation ,medicine.disease ,Clinical trial ,Oncology ,Amputation ,Sample size determination ,030220 oncology & carcinogenesis ,Physical therapy ,030211 gastroenterology & hepatology ,Sarcoma ,business ,Range of motion - Abstract
Background Survivors of lower extremity (LE) malignancies experience functional deficits. Purpose The purpose of this prospective clinical trial was to determine feasibility and functional outcomes of adding pre-habilitation during the 10-12 week period prior to a planned surgery to remove the tumor in children and adolescents with a LE sarcoma. Design Pilot study. Setting St. Jude Children's Research Hospital (SJCRH). Patients Participants included 14 individuals between the ages of 8 and 20 years who were diagnosed with a LE sarcoma. Participant outcomes were compared to a control group of 35 individuals treated for osteosarcoma that obtained the same functional assessments but no pre-habilitation. Intervention The intervention group received strengthening exercises and mobility training 3 times per week for 30-60 minutes for 10-12 weeks preoperatively. Measurements Participants completed the Functional Mobility Assessment (FMA) and measures of strength and range of motion (ROM) of bilateral lower extremities (BLEs) at baseline, after 10-12 weeks of preoperative PT, and at 20-22 weeks. Results Twelve participants completed at least 50% of their schedule pre-habilitative sessions. The intervention group scored significantly better on the FMA than the control group at weeks 20-22 (35.6 vs. 25.7, p .0267). No significant difference was found in ROM or strength. Limitations Due to this study being a pilot study, the sample size was small. Therefore, we cannot infer generalizability. Conclusions Findings suggest that those diagnosed with a LE malignancy awaiting a limb sparing procedure or amputation participate in at least 50% of scheduled PT sessions and benefit from them.
- Published
- 2017
6. Soft Tissue Sarcomas
- Author
-
Bhaskar N. Rao and Amos Loh Hong Pheng
- Subjects
musculoskeletal diseases ,Chemotherapy ,Pathology ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Mesenchyme ,medicine.medical_treatment ,Soft tissue sarcoma ,Soft tissue ,Skeletal muscle ,medicine.disease ,medicine.anatomical_structure ,Biopsy ,medicine ,Anatomic Location ,Rhabdomyosarcoma ,business - Abstract
Soft tissue sarcomas are a heterogenous group of malignant tumors that arise from primitive mesenchyme, and thus arise in any anatomic location. They are uncommon and account for 7.4% of all cancers in children under 20 years of age. They are classified into rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). RMS histologically resembles striated skeletal muscle, and is more common in children under 5 years of age. In contrast, NRSTS is more common in adolescents older than 10 years.
- Published
- 2019
7. Pulmonary Function after Treatment for Childhood Cancer. A Report from the St. Jude Lifetime Cohort Study (SJLIFE)
- Author
-
Bhaskar N. Rao, Kyla Shelton, Saumini Srinivasan, Nickhill Bhakta, Melissa M. Hudson, Daniel M. Green, Gregory T. Armstrong, Fariba Navid, Andrew M. Davidoff, Daniel A. Mulrooney, Matthew J. Krasin, Leslie L. Robison, Rohit P. Ojha, Kirsten K. Ness, Deokumar Srivastava, M. Beth McCarville, Ching-Hon Pui, Monika L. Metzger, Sheri L. Spunt, Dennis C. Stokes, Liang Zhu, and Mingjuan Wang
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Lung ,business.industry ,respiratory system ,Lung injury ,respiratory tract diseases ,Surgery ,Pulmonary function testing ,03 medical and health sciences ,FEV1/FVC ratio ,0302 clinical medicine ,medicine.anatomical_structure ,030228 respiratory system ,030220 oncology & carcinogenesis ,Diffusing capacity ,Relative risk ,Internal medicine ,medicine ,Lung volumes ,Prospective cohort study ,business - Abstract
Rationale: The relationship between treatment-related impairment of pulmonary function in adult survivors of childhood cancer and subsequent physical function has not been studied.Objectives: In this prospective evaluation of 606 adult survivors of childhood cancer, we sought to determine the risk factors for, as well as the functional impact of, clinically ascertained pulmonary function impairment.Methods: We measured FEV1, FVC, total lung capacity (TLC), and single-breath diffusing capacity of the lung for carbon monoxide corrected for hemoglobin (DlCOcorr), expressing the results as percent predicted and lower limit of normal (LLN) values, and we also assessed functional exercise capacity (6-minute-walk distance). Lung radiation exposure was expressed as the estimated percentage of lung tissue that received at least 10 Gy (V10). Associations of clinical and treatment factors with pulmonary function measures were assessed using log-binomial regression to calculate relative risks and 95% confidence inter...
- Published
- 2016
8. Initial diagnostic management of pediatric bone tumors
- Author
-
Michael D. Neel, Shenghua Mao, Armita Bahrami, Robert Gold, Amos Hong Pheng Loh, Alpin D. Malkan, Israel Fernandez-Pineda, Andrew M. Davidoff, Michael W. Bishop, Fazal N. Wahid, Rodrigo B. Interiano, Jianrong Wu, Bhaskar N. Rao, and Nathan Hinkle
- Subjects
Male ,Oncology ,Pathology ,medicine.medical_specialty ,Adolescent ,Biopsy ,Bone Neoplasms ,Diagnostic accuracy ,Sarcoma, Ewing ,Article ,030218 nuclear medicine & medical imaging ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,In patient ,Young adult ,Child ,Retrospective Studies ,Osteosarcoma ,medicine.diagnostic_test ,business.industry ,Infant ,Retrospective cohort study ,General Medicine ,medicine.disease ,Pediatric cancer ,Child, Preschool ,030220 oncology & carcinogenesis ,Pediatrics, Perinatology and Child Health ,Female ,Surgery ,Sarcoma ,business - Abstract
Osteosarcoma (OS) and the Ewing sarcoma family of tumors (ESFT) are the most common primary pediatric bone malignancies. We sought to assess the diagnostic accuracy of initial tumor biopsies in patients with OS or ESFT at a pediatric cancer center.All biopsies performed at initial presentation of patients with OS or ESFT at our institution from 2003 to 2012 were retrospectively reviewed. Diagnostic accuracy and incidence of complications were correlated with study variables using logistic regression analysis.One hundred forty-two biopsies were performed in 105 patients (median age 13.4years, range: 1.8-23.0), 104 (73.2%) OS and 38 (27.8%) ESFT. Thirty-one (21.8%) were performed on metastatic sites. Eighty-five (76.6%) of 111 primary site biopsies were open procedures, and 26 were percutaneous (23.4%). Primary site biopsies were successful in 94.1% of open and 73.1% of percutaneous procedures. Odds of obtaining a successful diagnostic specimen were 7.8 times higher with open approach (CI: 1.6-36.8). Metastatic site biopsies were successful in 66.7% of percutaneous and 100% of open and thoracoscopic procedures.Biopsy of metastatic sites was equal to primary site in obtaining diagnostic material with the added benefit of accurate staging, with few adverse events and high diagnostic yield.
- Published
- 2016
9. Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma
- Author
-
Vinay M. Daryani, Cynthia E. Herzog, Wayne L. Furman, Bhaskar N. Rao, Armita Bahrami, Fariba Navid, Jami S. Gattuso, Alberto S. Pappo, April Sykes, Sean Phipps, Wassim Chemaitilly, Belinda N. Mandrell, Andrew M. Davidoff, Jianrong Wu, Shenghua Mao, Deborah Schiff, John A. Sandoval, Barry L. Shulkin, and Clinton F. Stewart
- Subjects
0301 basic medicine ,medicine.medical_specialty ,business.industry ,Melanoma ,Alpha interferon ,Hematology ,Neutropenia ,medicine.disease ,Gastroenterology ,Surgery ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,Maintenance therapy ,Pegylated interferon ,030220 oncology & carcinogenesis ,Internal medicine ,Pediatrics, Perinatology and Child Health ,Cutaneous melanoma ,medicine ,Adjuvant therapy ,business ,Survival rate ,medicine.drug - Abstract
Background Pegylated interferon α-2b (IFN α-2b) improves disease-free survival in adults with resected stage III melanoma. We conducted a study to determine the feasibility and safety of incorporating pegylated IFN α-2b as adjuvant therapy in the treatment of children and adolescents with high-risk melanoma. Pharmacokinetic studies of IFN α-2b and neuropsychological and quality of life (OL) assessments were performed. Patient and Methods Eligible patients with resected American Joint Committee on Cancer Stage IIC, IIIA, and IIIB cutaneous melanoma received nonpegylated IFN α-2b 20 million units/m2/day intravenously 5 days per week for 4 weeks (induction) followed by pegylated IFN α-2b 1 μg/kg/dose weekly subcutaneously (SQ) for 48 weeks (maintenance). Results Twenty-three patients (15 females, median age 10 years) were enrolled. All patients completed induction therapy; five patients did not complete maintenance therapy either because of recurrent disease (n = 2) or toxicity (n = 3). The most common grade 3 and 4 toxicities of pegylated IFN α-2b were neutropenia (35%) and elevated liver transaminases (17%). The median nonpegylated IFN α-2b AUC0-∞ (5,026 pcg⋅hr/ml) was similar to adults. The median pegylated IFN α-2b exposure (48,480 pcg⋅hr/ml) was greater than the cumulative weekly exposure for nonpegylated IFN α-2b administered SQ three times per week (TIW). Validated measures demonstrated an improvement in QOL scores and no decline in psychological functioning over the course of therapy. Conclusions Pegylated IFN α-2b 1 μg/kg/dose SQ weekly as maintenance therapy in children and adolescents with high-risk melanoma is feasible with tolerable toxicity and appears to yield higher exposures than nonpegylated IFN α-2b administered SQ TIW.
- Published
- 2016
10. Gastrostomy Complications in Pediatric Cancer Patients: A Retrospective Single-Institution Review
- Author
-
Jianrong Wu, Israel Fernandez-Pineda, Stephen J. Shochat, Reagan M. Jones, Nana Boateng, Andrew M. Davidoff, Bhaskar N. Rao, and John A. Sandoval
- Subjects
medicine.medical_specialty ,business.industry ,Medical record ,medicine.medical_treatment ,Retrospective cohort study ,Hematology ,Perioperative ,Pediatric cancer ,Gastrostomy ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Statistical significance ,Pediatrics, Perinatology and Child Health ,medicine ,Absolute neutrophil count ,030211 gastroenterology & hepatology ,Complication ,business - Abstract
Background Complications in pediatric cancer patients after a gastrostomy (GT) placement have not been widely investigated. We aimed to evaluate the complication rate and nature of complications in this specific population. Procedure Medical records of pediatric cancer patients having a GT placed at our institution from 1998 to 2013 were retrospectively reviewed. Variables analyzed included gender, age, diagnosis, surgical procedure, GT device, duration of GT usage, absolute neutrophil count (ANC) level at surgery, and complications. Results One hundred seventy-one patients (92 males, 79 females), median age of 6 years (range, 0.2–21), who underwent 181 procedures (110 open, 59 endoscopic, and 12 laparoscopic) were identified. Diagnosis included central nervous system tumor (n = 101), solid tumor (n = 45), and leukemia/lymphoma (n = 25). A GT tube was used in 139 procedures and a GT button in 42. Median ANC level at procedure was 3,300/mm3 (range, 0–38,988). Median duration of GT usage was 8 months (range, 0.2–142). One hundred seventy-seven complications occurred in 106 patients (61.9%) and were categorized as perioperative ( 1 month after surgery, 79.7%). Major complications included 42 (23.7%) GT site infections and four (2.2%) intrabdominal complications. The most common minor complication was granulation tissue (28.8%). Younger age at procedure was associated with complications (P = 0.048) and an open technique was associated with GT site infection (P = 0.003). No statistical significance was observed between complications and gender, diagnosis, GT device, duration of GT usage, and ANC at procedure. Conclusions Younger patients were more likely to have complications, and GT site infections were more common after open GT procedures.
- Published
- 2016
11. Guidewire Catheter Exchange in Pediatric Oncology: Indications, Postoperative Complications, and Outcomes
- Author
-
Bhaskar N. Rao, Lucia Ortega-Laureano, Israel Fernandez-Pineda, Huiyun Wu, Andrew M. Davidoff, John A. Sandoval, Stephen J. Shochat, and Jianwrong Wu
- Subjects
medicine.medical_specialty ,Venipuncture ,business.industry ,medicine.medical_treatment ,Postoperative complication ,Retrospective cohort study ,Hematology ,Pediatric cancer ,Surgery ,03 medical and health sciences ,Catheter ,0302 clinical medicine ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Anesthesia ,Pediatrics, Perinatology and Child Health ,medicine ,Absolute neutrophil count ,030212 general & internal medicine ,Vein ,business ,Central venous catheter - Abstract
Background Maintaining long-term central venous catheters (CVCs) in children undergoing chemotherapy can be challenging. Guidewire catheter exchange (GCE) replaces a CVC without repeat venipuncture. This study evaluated the indications, success rate, and complications of GCE in a large cohort of pediatric cancer patients. Procedure Medical records of pediatric cancer patients who underwent GCE at our institution between 2003 and 2013 were retrospectively reviewed. Variables analyzed included gender, age at GCE, primary cancer diagnosis, indication for GCE, absolute neutrophil count (ANC) at GCE, vein used, success rate, and postoperative complications (
- Published
- 2016
12. Impact of Ovarian Transposition before Pelvic Irradiation on Ovarian Function among Long-term Survivors of Childhood Hodgkin Lymphoma: A Report from the St. Jude Lifetime Cohort Study
- Author
-
Daniel M. Green, Matthew J. Krasin, M. L. Metzger, Wassim Chemaitilly, Leslie L. Robison, D. Kumar Srivastava, Andrew M. Davidoff, Carmen L. Wilson, Ching-Hon Pui, Kirsten K. Ness, Lu Lu, Charles A. Sklar, Melissa M. Hudson, James L. Klosky, Israel Fernandez-Pineda, and Bhaskar N. Rao
- Subjects
Adult ,Organs at Risk ,medicine.medical_specialty ,Cyclophosphamide ,Adolescent ,Primary Ovarian Insufficiency ,Premature ovarian insufficiency ,Article ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,medicine ,Humans ,Fertility preservation ,Survivors ,Child ,Radiation Injuries ,Antineoplastic Agents, Alkylating ,Gynecology ,Pregnancy ,030219 obstetrics & reproductive medicine ,business.industry ,Hazard ratio ,Ovary ,Fertility Preservation ,Hematology ,medicine.disease ,Combined Modality Therapy ,Hodgkin Disease ,Confidence interval ,Oncology ,030220 oncology & carcinogenesis ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Cohort ,Female ,business ,Cohort study ,medicine.drug - Abstract
BACKGROUND We reviewed the effect of ovarian transposition (OT) on ovarian function among long-term survivors of childhood Hodgkin lymphoma (HL) treated with pelvic radiotherapy. PROCEDURE Female participants (age 18+ years) with HL in the St. Jude Lifetime Cohort Study (SJLIFE) were clinically evaluated for premature ovarian insufficiency (POI) 10 or more years after pelvic radiotherapy. Reproductive history including age at menopause and pregnancy/live births was available on all patients. RESULTS Of 127 eligible females with HL, 90 (80%) participated in SJLIFE, including 49 who underwent OT before pelvic radiotherapy. Median age at STLIFE evaluation was 38 years (range 25-60). In a multiple regression adjusted for age at diagnosis, pelvic radiotherapy doses > 1,500 cGy (hazard ratio [HR] = 25.2, 95% confidence interval [CI] = 3.1-207.3; P = 0.0027) and cumulative cyclophosphamide equivalent doses of alkylating agents > 12,000 mg/m2 (HR = 11.2, 95% CI = 3.4-36.8; P
- Published
- 2018
13. A comparison of function after limb salvage with non-invasive expandable or modular prostheses in children
- Author
-
Najat C. Daw, Victoria G. Marchese, Sue C. Kaste, Michael D. Neel, Bhaskar N. Rao, Kirsten K. Ness, and Catherine A. Billups
- Subjects
Male ,musculoskeletal diseases ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Limb salvage ,Artificial Limbs ,Bone Neoplasms ,Knee Joint ,Bone Sarcoma ,Prosthesis Design ,Article ,Bone Lengthening ,medicine ,Humans ,Range of Motion, Articular ,Paediatric patients ,Osteosarcoma ,business.industry ,Non invasive ,Prostheses and Implants ,Modular design ,Limb Salvage ,medicine.disease ,Leg Length Inequality ,Surgery ,Treatment Outcome ,Oncology ,Female ,Sarcoma ,Knee Prosthesis ,business - Abstract
Modular and non-invasive expandable prostheses have been developed to provide a functional knee joint that allows future expansion as growth occurs in the contralateral extremity in children with bone sarcomas that require removal of the growth plate. This study aimed to evaluate the functional outcomes of paediatric patients who received either a non-invasive expandable or modular prosthesis for bone sarcomas arising around the knee.We evaluated clinician-reported, patient-reported and measured function in 42 paediatric patients at least one year (median age at assessment 19.1 years) after limb salvage surgery, and compared patients who received modular system prostheses (N = 29, median age 15.5), who did not require lengthening procedures to those who received non-invasive expandable prostheses (N = 13, median age 11.1) requiring lengthening procedures (median 5).The number of revisions and time to first revision did not differ between the two groups. There were no differences between the two groups in total scores on the Enneking Musculoskeletal Tumor Society Scale, the Toronto Extremity Salvage Scale, and the Functional Mobility Assessment. Children with non-invasive expandable prostheses climbed stairs (11.93 ± 4.83 versus 16.73 ± 7.24 s, p = 0.02) in less time than those with modular prostheses.Our results suggest that the non-invasive expandable prosthesis produces similar functional results to the more traditional modular prosthesis.
- Published
- 2014
14. Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing
- Author
-
Shenghua Mao, Fariba Navid, Jennifer Willert, Najat C. Daw, Stacy L. Throm, Victor M. Santana, Bhaskar N. Rao, K. Elaine Harstead, Michael D. Neel, Clinton F. Stewart, David C. Turner, Burgess B. Freeman, David M. Loeb, and Jianrong Wu
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Time Factors ,Adolescent ,genetic structures ,Bevacizumab ,Population ,Angiogenesis Inhibitors ,Bone Neoplasms ,Antibodies, Monoclonal, Humanized ,Logistic regression ,Models, Biological ,Article ,Body Mass Index ,Pharmacokinetics ,Internal medicine ,medicine ,Humans ,Computer Simulation ,Dosing ,Child ,education ,Volume of distribution ,Osteosarcoma ,education.field_of_study ,Dose-Response Relationship, Drug ,business.industry ,Body Weight ,Surgery ,Clinical trial ,Logistic Models ,Area Under Curve ,Female ,business ,Body mass index ,Algorithms ,medicine.drug - Abstract
Purpose: To describe sources of interindividual variability in bevacizumab disposition in pediatric patients and explore associations among bevacizumab pharmacokinetics and clinical wound healing outcomes. Experimental Design: Before tumor resection, three doses of bevacizumab (15 mg/kg) were administered to patients (median age, 12.2 years) enrolled in a multi-institutional osteosarcoma trial. Serial sampling for bevacizumab pharmacokinetics was obtained from 27 patients. A population pharmacokinetic model was fit to the data, and patient demographics and clinical chemistry values were systematically tested as predictive covariates on model parameters. Associations between bevacizumab exposure and wound healing status were evaluated by logistic regression. Results: Bevacizumab concentration–time data were adequately described by a two-compartment model. Pharmacokinetic parameter estimates were similar to those previously reported in adults, with a long median (range) terminal half-life of 12.2 days (8.6 to 32.4 days) and a volume of distribution indicating confinement primarily to the vascular space, 49.1 mL/kg (27.1 to 68.3 mL/kg). Body composition was a key determinant of bevacizumab exposure, as body mass index percentile was significantly (P < 0.05) correlated to body-weight normalized clearance and volume of distribution. Furthermore, bevacizumab exposure before primary tumor resection was associated with increased risk of major wound healing complications after surgery (P < 0.05). Conclusion: A population pharmacokinetic model for bevacizumab was developed, which demonstrated that variability in bevacizumab exposure using weight-based dosing is related to body composition. Bevacizumab dosage scaling using ideal body weight would provide an improved dosing approach in children by minimizing pharmacokinetic variability and reducing likelihood of major wound healing complications. Clin Cancer Res; 20(10); 2783–92. ©2014 AACR.
- Published
- 2014
15. A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy
- Author
-
Michelle Kunkel, Wendene Smith, Shenghua Mao, Michael D. Neel, Bhaskar N. Rao, Vinay M. Daryani, Jianrong Wu, Fariba Navid, Alberto S. Pappo, Najat C. Daw, Catherine A. Billups, Barry L. Shulkin, Armita Bahrami, Deborah A. Ward, Clinton F. Stewart, Victor M. Santana, Jennifer Willert, David M. Loeb, and M. Beth McCarville
- Subjects
0301 basic medicine ,Male ,Vascular Endothelial Growth Factor A ,Cancer Research ,Time Factors ,medicine.medical_treatment ,Angiogenesis Inhibitors ,chemistry.chemical_compound ,0302 clinical medicine ,Postoperative Complications ,Antineoplastic Combined Chemotherapy Protocols ,Child ,Osteosarcoma ,Proteinuria ,Limb Salvage ,Vascular endothelial growth factor ,Bevacizumab ,Survival Rate ,Oncology ,030220 oncology & carcinogenesis ,Female ,medicine.symptom ,medicine.drug ,medicine.medical_specialty ,Adolescent ,Bone Neoplasms ,Amputation, Surgical ,Disease-Free Survival ,Drug Administration Schedule ,Article ,03 medical and health sciences ,Young Adult ,medicine ,Humans ,Survival rate ,Chemotherapy ,Wound Healing ,business.industry ,medicine.disease ,Surgery ,030104 developmental biology ,Methotrexate ,chemistry ,Amputation ,Doxorubicin ,Feasibility Studies ,Cisplatin ,business - Abstract
Increased vascular endothelial growth factor (VEGF) expression in osteosarcoma correlates with a poor outcome. We conducted a phase II trial to evaluate the feasibility and efficacy of combining bevacizumab, a monoclonal antibody against VEGF, with methotrexate, doxorubicin and cisplatin (MAP) in patients with localized osteosarcoma. Eligible patients received two courses of MAP chemotherapy before definitive surgery at week 10. Bevacizumab (15 mg/kg) was administered 3 days before starting chemotherapy then on day 1 of weeks 3 and 5 of chemotherapy. After surgery, patients received MAP for a total of 29 weeks; bevacizumab was added every 2 or 3 weeks on day 1 of chemotherapy at least 5 weeks after surgery. Group sequential monitoring rules were used to monitor for unacceptable bevacizumab-related targeted toxicity (grade 4 hypertension, proteinuria or bleeding, grade 3 or 4 thrombosis/embolism, and grade 2-4 major wound complications). Thirty-one patients (median age 12.8 years) with localized osteosarcoma were enrolled. No unacceptable targeted toxicities were observed except for wound complications (9 minor and 6 major), which occurred in 15 patients; none required removal of prosthetic hardware or amputation. The estimated 4-year event-free survival (EFS) rate and overall survival rate were 57.5 ± 10.0% and 83.4 ± 7.8%, respectively. Eight (28%) of 29 evaluable patients had good histologic response (
- Published
- 2016
16. Surgical Treatment of Pediatric Desmoid Tumors. A 12-Year, Single-Center Experience
- Author
-
John A. Sandoval, Miguel A. Soto-Miranda, Matt Krasin, Bhaskar N. Rao, Andrew M. Davidoff, Jon P. Ver Halen, Sheri L. Spunt, M.D. Neel, and Jesse J. Jenkins
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Adolescent ,Single Center ,Familial adenomatous polyposis ,Young Adult ,Surgical oncology ,medicine ,Humans ,Young adult ,Child ,Survival rate ,Neoplasm Staging ,Retrospective Studies ,business.industry ,Fibromatosis ,Infant ,Retrospective cohort study ,Prognosis ,medicine.disease ,Surgery ,Survival Rate ,body regions ,Fibromatosis, Aggressive ,Oncology ,Child, Preschool ,Lymphatic Metastasis ,Aggressive fibromatosis ,Female ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies - Abstract
Pediatric desmoid tumors (PDTs) represent a group of rare, distinct lesions. While sparse, available literature suggests that PDT are particularly aggressive and difficult to control when compared with their adult counterpart.A retrospective review identified 39 patients who underwent treatment of PDT at St. Jude Children's Research Hospital over a 12-year period. Clinicopathologic and treatment characteristics were analyzed to identify predictors of outcome.A total of 39 patients were treated during the study period, with a total number of 67 resections. Median age was 12.2 years; 49 % of patients were male, and 51 % were female. Median tumor size was 9.8 cm. PDT most commonly arose in the extremities (40 %), thorax (23 %), head and neck (21 %), and trunk (16 %). Also, 18 % of resections had negative margins (R0), 48 % were microscopic positive (R1), and 30 % were macroscopic positive (R2). The 1- and 5-year recurrence-free survival (RFS) was 97.1 and 73.1 %, respectively. Factors associated with worse RFS were patient age 12 years (HR = 5.08, p = 0.038) and tumor size 5 cm (HR = 1.22, p = 0.0597). Margin status did not affect RFS. Selective use of radiation therapy appeared to improve RFS.Our study suggests that margin status alone at the time of extirpation is not a predictor of ultimate cure or likelihood of recurrence. Many patients received adjuvant therapy, with benefits suggested after analysis. For patients with PDT, surgical extirpation should not come at the expense of functional preservation, as overall survival is excellent.
- Published
- 2013
17. Survival of pediatric patients after relapsed osteosarcoma: The St. Jude Children's Research Hospital experience
- Author
-
Amy W. Wozniak, Valerie McPherson, Jianrong Wu, Bhaskar N. Rao, Catherine A. Billups, Najat C. Daw, Michael D. Neel, and Sarah Leary
- Subjects
Cancer Research ,medicine.medical_specialty ,Chemotherapy ,Ifosfamide ,business.industry ,medicine.medical_treatment ,Cancer ,medicine.disease ,Confidence interval ,Surgery ,Metastasis ,Clinical trial ,Oncology ,Internal medicine ,medicine ,Osteosarcoma ,Methotrexate ,business ,medicine.drug - Abstract
BACKGROUND Chemotherapy has improved the outcome of patients with newly diagnosed osteosarcoma, but its role in relapsed disease is unclear. METHODS We reviewed the records of all patients who were treated for relapsed high-grade osteosarcoma at our institution between 1970 and 2004. Postrelapse event-free survival (PREFS) and postrelapse survival (PRS) were estimated, and outcome comparisons were made using an exact log-rank test. RESULTS The 10-year PREFS and PRS of the 110 patients were 11.8% ± 3.5% and 17.0% ± 4.3%, respectively. Metastasis at initial diagnosis (14%), and relapse in lung only (75%) were not significantly associated with PREFS or PRS. Time from initial diagnosis to first relapse (RL1) ≥18 months (43%), surgery at RL1 (76%), and ability to achieve second complete remission (CR2, 56%) were favorably associated with PREFS and PRS (P ≤ 0.0002). In patients without CR2, chemotherapy at RL1 was favorably associated with PREFS (P = 0.01) but not with PRS. In patients with lung relapse only, unilateral relapse and number of nodules ( ≤ 3) were associated with better PREFS and PRS (P ≤ 0.0005); no patients with bilateral relapse survived 10 years. The median PREFS after treatment with cisplatin, doxorubicin, methotrexate, and ifosfamide was 3.5 months (95% confidence interval, 2.1-5.2), and the median PRS was 8.2 months (95% confidence interval, 5.2-15.1). CONCLUSIONS Late relapse, surgical resection, and unilateral involvement (in lung relapse only) favorably impact outcome after relapse. Surgery is essential for survival; chemotherapy may slow disease progression in patients without CR2. These data are useful for designing clinical trials that evaluate novel agents. Cancer 2013;119:2645-2653. © 2013 American Cancer Society.
- Published
- 2013
18. Thoracoscopic resection of computed tomography-localized lung nodules in children
- Author
-
Robert Gold, John Uffman, Bhaskar N. Rao, Israel Fernandez-Pineda, Andrew M. Davidoff, and Lalit Parida
- Subjects
Male ,medicine.medical_specialty ,Lung Neoplasms ,Adolescent ,Radiography ,Computed tomography ,Hook wire ,Radiography, Interventional ,Article ,Resection ,Young Adult ,Postoperative Complications ,medicine ,Thoracoscopy ,Humans ,Child ,Lung ,medicine.diagnostic_test ,business.industry ,Infant ,Solitary Pulmonary Nodule ,Cancer ,General Medicine ,medicine.disease ,Pediatric cancer ,Treatment Outcome ,medicine.anatomical_structure ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Female ,Surgery ,Radiology ,Neoplasm Recurrence, Local ,Tomography, X-Ray Computed ,business - Abstract
Detection and treatment of small lung nodules are important in managing pediatric cancer. We studied the effectiveness of preoperative localization of pulmonary nodules by CT-guided needle hook wire placement followed by thoracoscopic resection in children with cancer.We reviewed records of patients who underwent thoracoscopic resection of lung nodules localized preoperatively with CT-guided needle and hook wire placement at our hospital between March 1999 and April 2010 for nodule characteristics and outcomes of procedure.Thirty-seven patients (median age, 14years) with osteosarcoma or other cancers underwent thoracoscopic resection of needle-localized lung nodules. Lesion (median nodule size, 4mm) location was left lung (n=11), right lung (n=19), and bilateral (n=7). The procedure was successful in 36 (97.3%) patients. Five patients had a pneumothorax after localization but none required chest tube placement before thoracoscopy. All patients underwent thoracoscopy, but 4 required conversion to open thoracotomy. During thoracoscopic inspection, the hook wire slipped out of the lesion in 6 patients, of whom 1 needed thoracotomy to locate nodule. Lesions (malignant in 13 patients) were removed in all patients. Five patients with benign lesions had recurrent malignant lung nodules.Thoracoscopic resection of preoperatively localized small lung nodules is a safe and effective procedure in children.
- Published
- 2013
19. Analysis of Prognostic Factors in Extraosseous Ewing Sarcoma Family of Tumors: Review of St. Jude Children’s Research Hospital Experience
- Author
-
Matthew J. Krasin, Jianrong Wu, Catherine A. Billups, Jason W. Denbo, Andrew M. Davidoff, Fariba Navid, Bhaskar N. Rao, and W. Shannon Orr
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Bone Neoplasms ,Sarcoma, Ewing ,Hospital experience ,Young Adult ,Surgical oncology ,Humans ,Medicine ,Child ,Survival rate ,Neoplasm Staging ,Retrospective Studies ,Extraosseous Ewing Sarcoma ,business.industry ,Infant ,Local failure ,Retrospective cohort study ,Prognosis ,medicine.disease ,Combined Modality Therapy ,Survival Rate ,Oncology ,Child, Preschool ,Female ,Surgery ,Neoplasm staging ,Sarcoma ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies - Abstract
Advances in the treatment of Ewing sarcoma family of tumors (ESFT) are the result of improvements in systemic and local therapies. Clinical data of extraosseous ESFT are scarce.A retrospective analysis of all patients with extraosseous ESFT treated at St. Jude Children's Research Hospital (SJCRH) from June 1982 to August 2009.Forty-six patients with extraosseous ESFT were identified. The mean age at diagnosis was 13.8 years. The majority of patients were male and white. The most common site of primary tumor was the trunk. Twelve patients had subcutaneous tumors. The median tumor size was 8 cm. Six patients (13 %) had metastatic disease at diagnosis. A total of 59 % of patients were alive at the time of analysis, with a median follow-up from diagnosis of 15.3 years. Fifteen-year estimates of survival and event-free survival (EFS) for all patients were 53.3 ± 9.4 and 50 ± 9.1 %, respectively. Fifteen-year estimates of survival and EFS with localized disease were 61.4 ± 9.8 and 57.6 ± 9.7 %, respectively. Stage and subcutaneous ESFT were significant predictors of outcome. There was no significant difference in patient's demographics and tumor characteristics between patients with skeletal ESFT and extraosseous Ewing sarcoma. The outcome for patients with localized extraosseous Ewing sarcoma was similar to that reported for all localized ESFT patients treated at SJCRH.The outcome for localized patients treated with extraosseous ESFT was similar to that reported for all ESFT patients treated on protocols at SJCRH. Patients with subcutaneous ESFT had a favorable prognosis when compared to their counterparts.
- Published
- 2012
20. Patients with osteosarcoma with a single pulmonary nodule on computed tomography: a single-institution experience
- Author
-
Liza J. Emanus, Stephen J. Shochat, Beth McCarville, Andrew M. Davidoff, Israel Fernandez-Pineda, Bhaskar N. Rao, and Najat C. Daw
- Subjects
medicine.medical_specialty ,Lung Neoplasms ,Adolescent ,medicine.medical_treatment ,Salvage therapy ,Bone Neoplasms ,Computed tomography ,Unnecessary Procedures ,Article ,Disease-Free Survival ,Young Adult ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Thoracotomy ,Child ,Retrospective Studies ,Salvage Therapy ,Osteosarcoma ,Solitary pulmonary nodule ,medicine.diagnostic_test ,Thoracic Surgery, Video-Assisted ,business.industry ,Patient Selection ,Solitary Pulmonary Nodule ,Retrospective cohort study ,General Medicine ,medicine.disease ,Combined Modality Therapy ,Tennessee ,Cardiothoracic surgery ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Disease Progression ,Surgery ,Radiology ,Tomography ,business ,Tomography, Spiral Computed ,Follow-Up Studies - Abstract
The purpose of this study is to determine if patients with osteosarcoma (OS) with metachronous metastatic pulmonary disease presenting with a single pulmonary nodule (SPN) on computed tomography (CT) were found to have other lesions at the time of thoracotomy.Data were collected retrospectively on consecutive patients with OS treated at our institution from 1982 to 2007. Patients with no evidence of disease at the end of initial therapy who subsequently relapsed in the lung were identified.In our study, 16 (8%) of 198 patients with OS with metachronous metastatic pulmonary disease presented with a SPN on CT scan. In all patients, only 1 metastatic nodule for OS was found at the time of thoracotomy. The median time between diagnosis and first lung relapse was 23.8 months (range, 4-80 months). Eleven patients (68.7%) subsequently had a second lung relapse, but only 3 patients had involvement of the ipsilateral lung (mean time interval between first and second pulmonary relapses of 17 months; range, 2-44 months). Five-year overall survival from diagnosis was 56.2%. Seven patients (43.8%) died of disease progression.In our experience, patients with OS with metachronous metastatic pulmonary disease presenting with a SPN on CT were not found to have additional malignant lesions at the time of thoracotomy. Consideration should be given in this group of selected patients to use a minimally invasive approach to nodule removal with image-guided localization, if needed, rather than open thoracotomy because ipsilateral metastases are not likely to be found.
- Published
- 2012
21. Safety of central venous catheter placement at diagnosis of acute lymphoblastic leukemia in children
- Author
-
Amy W. Wozniak, C H Pui, Bhaskar N. Rao, Andrew M. Davidoff, G. Gonzalez, Stephen J. Shochat, Scott C. Howard, and Jerry L. Shenep
- Subjects
medicine.medical_specialty ,Pediatrics ,business.industry ,medicine.medical_treatment ,Incidence (epidemiology) ,Retrospective cohort study ,Hematology ,equipment and supplies ,medicine.disease ,Pediatric cancer ,Thrombosis ,Surgery ,Catheter ,Oncology ,Pediatrics, Perinatology and Child Health ,medicine ,Infection control ,business ,Central venous catheter ,Cohort study - Abstract
Background Central venous catheters (CVC) facilitate the management of patients with cancer. Optimal timing for placement of a CVC is controversial. We sought to determine whether early placement in children with acute lymphoblastic leukemia (ALL), a group at high risk for infection and thrombosis, was associated with an increased rate of surgical complications. Procedure We evaluated the incidence and risk factors for early surgical complications in children with ALL diagnosed between 2004 and 2009 at a single pediatric cancer center. Results One hundred seventy-two patients were studied. There were 17 episodes of bloodstream infection, for a 30-day incidence of 9.8% (95% CI, 5.9–15%). There were no surgical site infections and no CVC was removed due to infection. Early thrombosis occurred in only one patient, 3 days after CVC placement. Infection was not influenced by catheter type, patient age, body mass index, or fever at the time of placement. The infection rate was not statistically higher when the ANC was
- Published
- 2011
22. Frontline treatment of localized osteosarcoma without methotrexate
- Author
-
Milena Villarroel, Najat C. Daw, Juan Quintana, Michael D. Neel, Lori Luchtman-Jones, Victor M. Santana, Bhaskar N. Rao, Catherine A. Billups, Jesse J. Jenkins, and Jianrong Wu
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Bone Neoplasms ,Article ,Carboplatin ,chemistry.chemical_compound ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Ifosfamide ,Child ,neoplasms ,Cisplatin ,Osteosarcoma ,Chemotherapy ,business.industry ,Standard treatment ,medicine.disease ,Surgery ,chemistry ,Doxorubicin ,Child, Preschool ,Localized disease ,Female ,Methotrexate ,business ,medicine.drug - Abstract
The standard treatment of osteosarcoma includes cisplatin and high-dose methotrexate (HDMTX); both agents exert significant toxicity, and HDMTX requires complex pharmacokinetic monitoring and leucovorin rescue. In the previous OS91 trial, the treatment of localized disease with carboplatin, ifosfamide, doxorubicin, and HDMTX yielded outcomes comparable to those of cisplatin-based regimens and caused less toxicity. To build on this experience, the authors conducted a multi-institutional trial (OS99) that evaluated the efficacy of carboplatin, ifosfamide, and doxorubicin without HDMTX in patients with newly diagnosed, localized, resectable osteosarcoma.Treatment was comprised of 12 cycles of chemotherapy administered over 35 weeks: 3 cycles of carboplatin (dose targeted to area under the concentration-time curve of 8 mg/mL × min on Day 1) and ifosfamide (at a dose of 2.65 g/m(2) daily ×3 days) and 1 cycle of doxorubicin (at a dose of 25 mg/m(2) daily ×3 days) before surgical resection, followed by 2 additional cycles of the combination of carboplatin and ifosfamide and 3 cycles each of doxorubicin (25 mg/m(2) daily ×2 days) combined with ifosfamide or carboplatin.A total of 72 eligible patients (median age, 13.4 years) were enrolled between May 1999 and May 2006. Forty of the 66 (60.6%) evaluable patients had good histologic responses (90% tumor necrosis) to preoperative chemotherapy. The estimated 5-year event-free survival rate was 66.7% ± 7.0% for the OS99 trial compared with 66.0% ± 6.8% for the OS91 trial (P = .98). The estimated 5-year survival rate was 78.9% ± 6.3% for the OS99 trial and 74.5% ± 6.3% for the OS91 trial (P = .40).The regimen used in the OS99 trial was found to produce outcomes comparable to those of cisplatin-containing or HDMTX-containing regimens. This therapy offers a good alternative for patients, particularly those who demonstrate an intolerance of HDMTX, and for institutions that cannot provide pharmacokinetic monitoring for MTX.
- Published
- 2011
23. Seven-year experience of using Repiphysis® expandable prosthesis in children with bone tumors
- Author
-
Raya Saab, Said Saghieh, Rachid Haidar, Miguel R. Abboud, Samar Muwakkit, and Bhaskar N. Rao
- Subjects
High rate ,Limb salvage surgery ,medicine.medical_specialty ,Bone cancer ,business.industry ,medicine.medical_treatment ,Leg length ,Hematology ,Bone Sarcoma ,medicine.disease ,Skeletal maturity ,Prosthesis ,Surgery ,Blood cancer ,Oncology ,Pediatrics, Perinatology and Child Health ,medicine ,business - Abstract
Background Results of the use of the non-invasive expandable endoprosthetic device Repiphysis® in limb salvage surgery for skeletally immature children with bone cancer have been promising. Procedure In this report, we analyze the outcomes and complications associated with using 17 Repiphysis® prosthesis from January 2002 to March 2009 in 17 skeletally immature children with bone sarcoma around the knee. Results The average follow-up was 61.7 months. All patients who underwent active expansion experienced successful lengthening with a total of 38 lengthening sessions and an average of 8.6 mm gained per session. The Musculoskeletal Tumor Society functional scores averaged 90% at the most recent follow-up. The average survival time of the device from implementation to revision or last follow-up was 2 years and 8 months. There were 12 complications in 12 patients, including 6 mechanical problems, 2 tibial fractures and 3 infections. For the 17 insertions, 7 revision operations were performed, 3 of which were done using a new Repiphysis® device. Conclusions Despite the high rate of complications, the goal of achieving equal leg length at skeletal maturity with fewer surgeries per patient has been relatively achieved with the use of this device. Pediatr Blood Cancer. 2010;55:457–463. © 2010 Wiley-Liss, Inc.
- Published
- 2010
24. Pediatric gastrointestinal stromal tumors: a commentary on the value of referral clinics for rare pediatric tumors
- Author
-
Israel Fernandez-Pineda and Bhaskar N. Rao
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Population ,Gastroenterology ,symbols.namesake ,Growth factor receptor ,Internal medicine ,Medicine ,education ,neoplasms ,Gastrointestinal tract ,Chemotherapy ,education.field_of_study ,Hepatology ,GiST ,biology ,business.industry ,Imatinib ,digestive system diseases ,Interstitial cell of Cajal ,biology.protein ,symbols ,business ,Platelet-derived growth factor receptor ,medicine.drug - Abstract
Gastrointestinal stromal tumors (GIST) are mesenchymal neoplasms of the gastrointestinal tract that originates from intestinal pacemaker cells, also known as interstitial cells of Cajal (1). Most cases are seen in adults between the 4 th and 6 th decade of life. Children and adolescents are rarely affected, and only 1.4% to 2.7% of all GISTs occur in this population (2). The most common clinical scenario in younger patients is the diagnosis of a gastric GIST that usually occurs in adolescent females (3). Pediatric GIST has unique clinical, biological and genetic features that are distinct from adulthood GIST (4). While most GISTs in adults have an activating mutation of the KIT or platelet-derived growth factor receptor (PDGFR) proto-oncogenes, this is only present in only 10% of pediatric GISTs. GISTs that lack KIT or PDGFR mutations are considered wild-type GISTs (WT-GISTs) (5). Several receptor tyrosine kinase inhibitors such as Imatinib have proven effective in treating GIST that shows KIT or PDGFR mutations (6). Treatment of GIST is based on surgical resection with negative margins, since it is resistant to chemotherapy and radiation. The addition of receptor tyrosine kinase inhibitors is recommended for patients with KIT or PDGFR mutations.
- Published
- 2017
25. Body wall and visceral nonrhabdomyosarcoma soft tissue sarcomas in children and adolescents
- Author
-
Andrew M. Davidoff, Matthew J. Krasin, Sheri L. Spunt, Bhaskar N. Rao, JoAnn Harper, Catherine A. Billups, and Fariba Navid
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Soft Tissue Neoplasms ,Gastroenterology ,Disease-Free Survival ,Article ,Abdominal wall ,Risk Factors ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Outcome Assessment, Health Care ,medicine ,Humans ,Cumulative incidence ,Child ,Clinical Trials as Topic ,Retrospective review ,Chemotherapy ,business.industry ,Abdominal Wall ,Age Factors ,Infant, Newborn ,Infant ,Soft tissue ,Sarcoma ,General Medicine ,medicine.disease ,Combined Modality Therapy ,Surgery ,Radiation therapy ,Viscera ,Treatment Outcome ,medicine.anatomical_structure ,Chemotherapy, Adjuvant ,Abdominal Neoplasms ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Cohort ,Female ,Radiotherapy, Adjuvant ,business - Abstract
Predictors of outcome have not been established for pediatric visceral and body wall nonrhabdomyosarcoma soft tissue sarcomas (NRSTS).The study used a retrospective review of clinical features and outcome of 61 patients with visceral and body wall NRSTS evaluated at our institution between March 1962 and December 1999.Median age at diagnosis was 9.9 years (range, birth to 17.4 years). Tumors were greater than 5 cm in 43 (70%), high grade in 33 (54%), invasive in 25 (41%), and metastatic at presentation in 14 (23%) patients. Visceral tumors (n = 27) were more likely than body wall tumors (n = 34) to be greater than 5 cm (93% vs 53%; P.001) and invasive (70% vs 18%; P.001) and were less likely to be resected at diagnosis (44% vs 85%; P = .001). Estimated 10-year event-free survival (EFS) and overall survival (OS) for the entire cohort were 45.5% +/- 6.9% and 56.8% +/- 6.7%, respectively. The 10-year EFS and OS were better for patients with body wall sites than for those with visceral sites (61.8% +/- 8.5% and 67.5% +/- 8.2% vs 24.2% +/- 9.4% and 43.0% +/- 10.3%; P = .004 and P = .004). The 10-year estimated cumulative incidence (CI) of local recurrence was higher for patients with visceral sites than for those with body wall sites (64.3% +/- 9.8% vs 26.5% +/- 7.7%; P = .004), whereas CI of distant recurrence was similar for the 2 sites (15.2% +/- 7.2% vs 23.5% +/- 7.4%; P = .39).Pediatric patients with visceral NRSTS are more likely to have invasive, large, and unresectable tumors compared to those with body wall tumors. More than two thirds of visceral NRSTS recur locally, and fewer than half of patients with visceral tumors survive.
- Published
- 2009
26. Limb salvage surgery for children and adolescents with malignant bone tumors in a developing country
- Author
-
Peter Noun, Samar Muwakitt, Fadi S. Farhat, Roula Farah, Samir Akel, Bassem I. Razzouk, Rami Kamzoul, Said Sagghieh, Carlos Rodriguez Galindo, Hassan Khalifeh, Miguel R. Abboud, Rachid Haidar, Ghina R. Mumtaz, and Bhaskar N. Rao
- Subjects
Adult ,Male ,medicine.medical_specialty ,Limb salvage surgery ,Adolescent ,medicine.medical_treatment ,Developing country ,Bone Neoplasms ,Sarcoma, Ewing ,Femoral stem ,Young Adult ,Bone Lengthening ,medicine ,Humans ,Lebanon ,Child ,Developing Countries ,Osteosarcoma ,Chemotherapy ,business.industry ,Wound dehiscence ,Rotationplasty ,Extremities ,Hematology ,Limb Salvage ,medicine.disease ,Surgery ,Survival Rate ,Treatment Outcome ,Oncology ,Pediatrics, Perinatology and Child Health ,Female ,Sarcoma ,business - Abstract
PURPOSE: To describe the 5-year experience of a multidisciplinary limb salvage program for children and adolescents with malignant bone tumors in Lebanon. PATIENTS AND METHODS: Between January 2002 to February 2007, 30 children and adolescents (2 with Ewing sarcoma and 28 with osteosarcoma) underwent Limb Salvage Surgeries (LSS) at the American University of Beirut Medical Center after partnering with the multidisciplinary team at St. Judes Children's Research Hospital (SJCRH). Procedures performed included 12 Repiphysis, noninvasively expandable, prostheses inserted in skeletally immature children, 15 modular prostheses, 2 allografts and 1 rotationplasty. All patients received pre- and postoperative chemotherapy. RESULTS: With a mean follow-up of 31 months, 20 patients are now off therapy, 4 died, and 6 are receiving chemotherapy (3 due to pulmonary recurrence). Complications of surgery included infections in three cases, failure of the expansion mechanism in two, femoral stem fracture in one, prostheses femoral stem loosening in one and wound dehiscence in one. Lengthening of Repiphysis prostheses was achieved by subjecting the limb to an electromagnetic field that would allow controlled release of the Repiphysis expansion mechanism. Ten patients underwent a total of 42 lengthening procedures with an average of 9 mm lengthened per procedure (range 2-15 mm). All patients have good function of the affected limb. CONCLUSION: Our LSS results are comparable to those reported in the literature. Collaboration with SJCRH and fund raising were critical to the program's success. This endeavor could serve as a model for establishing LSS programs in developing countries.
- Published
- 2008
27. Prognostic factors for local and distant control in Ewing sarcoma family of tumors
- Author
-
Catherine A. Billups, Carlos Rodriguez-Galindo, Tiebin Liu, Matthew J. Krasin, Bhaskar N. Rao, and Fariba Navid
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Antineoplastic Agents ,Bone Neoplasms ,Sarcoma, Ewing ,Medical Records ,Risk Factors ,Internal medicine ,medicine ,Humans ,Cumulative incidence ,Ifosfamide ,Treatment Failure ,Child ,Etoposide ,Neoplasm Staging ,Retrospective Studies ,business.industry ,Incidence ,Infant ,Ewing's sarcoma ,Cancer ,Retrospective cohort study ,Hematology ,Prognosis ,medicine.disease ,Pediatric cancer ,Surgery ,Radiation therapy ,Chemotherapy, Adjuvant ,Child, Preschool ,Localized disease ,Female ,Radiotherapy, Adjuvant ,Dose Fractionation, Radiation ,Sarcoma ,Neoplasm Recurrence, Local ,business - Abstract
Background: Advances in the treatment of Ewing sarcoma family of tumors (ESFT) are the result of improvements in systemic and local therapies. The individual contributions of each treatment component cannot be analyzed separately; improvements in local and systemic control can influence each other. Patients and methods: We reviewed the records of 220 patients treated on institutional protocols from 1979 to 2004. Factors predictive of local and distant recurrence were analyzed. Results: The median age at diagnosis was 13.7 years. Ninety-five patients relapsed at a median of 1.6 years. The 5-year overall survival estimate was 63.5% 6 3.5%. The estimated 5-year cumulative incidence (CI) of local failure was 25.1% 6 3.0%. Local failure was associated with treatment era (P < 0.001), tumor size (P = 0.037) and type of local control (P = 0.021). Systemic treatment intensification improved local control. The estimated 5-year CI of distant recurrence was 22.5% 6 2.9%. Patients with localized disease (P < 0.001), smaller tumors (P = 0.018) and those who received surgery 6 radiation for local control (P = 0.023) had lower CI of distant failure. Conclusions: Successful treatment of ESFT requires optimal systemic and local therapy. Both treatment modalities are intertwined and the control of both local and distant disease is the result of the combined approach.
- Published
- 2008
28. Colorectal Carcinoma in Childhood and Adolescence: A Clinicopathologic Review
- Author
-
D. Ashley Hill, Catherine A. Billups, Alvida M. Cain, Bhaskar N. Rao, Shannon E. Riedley, Wayne L. Furman, Charles B. Pratt, and Sheri L. Spunt
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Abdominal pain ,Adolescent ,Colorectal cancer ,Gastroenterology ,Cohort Studies ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Stage (cooking) ,Child ,Survival analysis ,business.industry ,Cancer ,Prognosis ,medicine.disease ,Adenocarcinoma, Mucinous ,Survival Analysis ,digestive system diseases ,Colon polyps ,Treatment Outcome ,Oncology ,Adenocarcinoma ,Female ,medicine.symptom ,Colorectal Neoplasms ,business ,Cohort study - Abstract
Purpose Pediatric colorectal carcinoma (CRC) is rare, but the available data suggest that it is more likely than adult CRC to be advanced at presentation and to have a poor outcome. We sought to better characterize pediatric CRC. Patients and Methods We reviewed the clinical and pathologic features, prognostic factors, and outcome of CRC in 77 children and adolescents (ages 7 to 19 years) referred to St Jude Children's Research Hospital between 1964 and 2003. Results At presentation, 76 patients had one or more signs or symptoms of CRC (abdominal pain, altered bowel habits, weight loss, anemia). Tumors were evenly distributed between the right and left colon; 62% were mucinous adenocarcinoma. At presentation, 86% of patients had advanced-stage disease; more than half had distant metastases. Overall outcome was poor. Advanced stage and mucinous histology were significant predictors of adverse outcome. Stage-specific survival at 10 years was 67% ± 27% (stage 1), 38% ± 15% (stage 2), 28% ± 11% (stage III), and 7% ± 4% (stage 4). Although no patient had a diagnosis of polyposis syndrome before diagnosis of CRC, 17 (22%) had colon polyps and eight (including two who previously underwent pelvic radiotherapy) had multiple polyps. Conclusion Initial signs and symptoms of CRC are similar in pediatric and adult patients. The strikingly higher frequency of mucinous histology suggests that the biology of CRC differs in pediatric and adult patients and may contribute to poor outcomes. Children should be included in prospective clinical trials for CRC.
- Published
- 2007
29. Pleurodesis for effusions in pediatric oncology patients at end of life
- Author
-
Pamela S. Hinds, Michael L. Hancock, Bhaskar N. Rao, Shesh N. Rai, Nikita Oigbokie, and Fredric A. Hoffer
- Subjects
Adult ,Male ,medicine.medical_specialty ,Palliative care ,Adolescent ,Pleural effusion ,medicine.medical_treatment ,MEDLINE ,Oxygen Consumption ,Neoplasms ,Pediatric oncology ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Child ,Intensive care medicine ,Survival rate ,Device Removal ,Pleurodesis ,Retrospective Studies ,Neuroradiology ,Terminal Care ,business.industry ,Respiration ,Palliative Care ,Retrospective cohort study ,medicine.disease ,Patient Discharge ,Pleural Effusion, Malignant ,Survival Rate ,Chest Tubes ,Child, Preschool ,Doxycycline ,Pediatrics, Perinatology and Child Health ,Female ,business ,Follow-Up Studies - Abstract
Pleurodesis for end-of-life care has been used in adults for decades, but little is known about the usefulness of this technique in improving the quality of care for pediatric patients.To assess whether intractable pleural effusions in pediatric oncology patients at end of life could be sufficiently relieved by pleurodesis.Eleven pleurodeses were performed with doxycycline in seven pediatric cancer patients (age 3-21 years) with intractable pleural effusions at the end of life. Five patients had unilateral pleurodeses and two had a unilateral followed by bilateral pleurodeses.Respiratory rates decreased in all seven patients (P = 0.016) and aeration improved significantly after chest tube placement (P = 0.033). The chest tubes were placed a median of 1 day before pleurodesis. Eight of nine chest tubes (89%) were removed before discharge at a median of 3 days after pleurodesis. Pain secondary to the pleurodesis lasted 1 day or less. Improvement in the respiratory rate remained after pleurodesis and chest tube removal (P = 0.031). Five of seven patients (70%) were able to leave the hospital to return home. The five patients discharged lived 10 to 49 days (median 19 days) after discharge.Pediatric oncology patients with intractable effusions at end of life can have respiratory benefit from pleurodeses and, as a result, are more likely to return home for terminal care.
- Published
- 2007
30. Analysis of prognostic factors in ewing sarcoma family of tumors
- Author
-
Tiebin Liu, Matthew J. Krasin, Carlos Rodriguez-Galindo, Bhaskar N. Rao, Najat C. Daw, Fariba Navid, Jianrong Wu, Sheri L. Spunt, Catherine A. Billups, and Victor M. Santana
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Sarcoma, Ewing ,Internal medicine ,Epidemiology ,medicine ,Humans ,Risk factor ,Child ,Retrospective Studies ,Medical Audit ,business.industry ,Incidence (epidemiology) ,Infant ,Cancer ,Neoplasms, Second Primary ,Retrospective cohort study ,Prognosis ,medicine.disease ,Pediatric cancer ,Surgery ,Treatment Outcome ,Child, Preschool ,Localized disease ,Female ,Sarcoma ,business - Abstract
BACKGROUND. Advances in systemic and local therapies have improved outcomes for patients with the Ewing sarcoma family of tumors (ESFT). As new treatments are developed, a critical review of data from past treatment eras is needed to identify clinically relevant risk groups. METHODS. The authors reviewed the records of 220 patients with ESFT who were treated on protocols at St. Jude Children’s Research Hospital from 1979 to 2004. Two treatment eras were defined. Factors predictive of outcome were analyzed to identify distinct risk groups. RESULTS. The median age at diagnosis was 13.7 years (range, 1.1–25.2 years). Metastatic disease was associated with tumors measuring [ 8c m (P 5 .002) and axial location (P 5 .014). The 5-year overall survival (OS) estimate (63.5% � 3.5%) did not appear to differ by protocol. Tumor stage and size were found to be the only independent predictors of outcome. Treatment era and type of local control therapy were found to influence the outcome of patients with localized disease. Four risk groups were defined: favorable risk (age
- Published
- 2007
31. Current Management of Neonatal Soft-tissue Sarcomas and Benign Tumors with Local Aggressiveness
- Author
-
Bhaskar N. Rao, Israel Fernandez-Pineda, and Michael D. Neel
- Subjects
Parents ,medicine.medical_specialty ,Routine ultrasound ,medicine.medical_treatment ,Directive Counseling ,Context (language use) ,Prenatal diagnosis ,Antineoplastic Agents ,Soft Tissue Neoplasms ,Infant, Newborn, Diseases ,Pregnancy ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Neoplasm Invasiveness ,Rhabdomyosarcoma ,Hemangiopericytoma ,business.industry ,Infant, Newborn ,Soft tissue ,Radiotherapy Dosage ,Sarcoma ,medicine.disease ,Prognosis ,Radiation therapy ,Fetal Diseases ,Current management ,Pediatrics, Perinatology and Child Health ,Female ,Interdisciplinary Communication ,Radiology ,business - Abstract
Neonatal soft-tissue tumors are rare and comprise a heterogeneous group of neoplasms with substantial histological diversity. Treatment options include careful observation, primary surgical resection or medical therapy. Although histologically benign, some neoplasms do exhibit an aggressive local behavior. The most common soft-tissue sarcomas in this age group include rhabdomyosarcoma, fibrosarcoma, malignant rhabdoid tumor and hemangiopericytoma. Prenatal diagnosis on routine ultrasound or in the context of a known predisposition syndrome is increasingly becoming more common. Management of neonatal tumors requires a multidisciplinary team that includes obstetricians, neonatologists, pediatric oncologists, pediatric surgical specialists and psychological support for the family members. Treatment is particularly challenging due to the difficulty in appropriate dosing of chemotherapeutic agents or the limitations of the use of radiation therapy. Although surgical treatment is predominant in this age group, close observation may be appropriate, since spontaneous regression has been reported for certain histological subtypes.
- Published
- 2015
32. A comparative analysis of functional outcomes in adolescents and young adults with lower‐extremity bone sarcoma
- Author
-
Shesh N. Rai, Elena M. Spearing, Pamela S. Hinds, Claire A. Carlson, Bhaskar N. Rao, Anna T. Meadows, Jill P. Ginsberg, Michael D. Neel, Victoria G. Marchese, Lijun Zhang, and Lulie Callaway
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Knee Joint ,Rotation ,medicine.medical_treatment ,Bone Neoplasms ,Bone Sarcoma ,Amputation, Surgical ,Disability Evaluation ,Physical medicine and rehabilitation ,Bones of Lower Extremity ,Quality of life ,Humans ,Medicine ,Femur ,Prospective Studies ,Mobility Limitation ,Young adult ,Prospective cohort study ,business.industry ,Rotationplasty ,Sarcoma ,Recovery of Function ,Hematology ,Limb Salvage ,medicine.disease ,Treatment Outcome ,Oncology ,Amputation ,Pediatrics, Perinatology and Child Health ,Quality of Life ,Physical therapy ,Female ,business ,Follow-Up Studies - Abstract
Background Comparison of functional mobility and quality of life is performed in patients with lower-extremity bone sarcoma following either amputation, limb-sparing surgery, or rotationplasty with four different types of outcome measures: (1) an objective functional mobility measure that requires patients to physically perform specific tasks, functional mobility assessment (FMA); (2) a clinician administered tool, Musculoskeletal Tumor Society Scale (MSTS); (3) a patient questionnaire, Toronto Extremity Salvage Scale (TESS); and (4) a health-related quality of life (HRQL) measure, Short Form-36 version 2 (SF-36v.2). Procedure This is a prospective multi-site study including 91 patients with lower-extremity bone sarcoma following amputation, limb-sparing surgery, or rotationplasty. One of three physical therapists administered the quality of life measure (SF-36v.2) as well as a battery of functional measures (FMA, MSTS, and TESS). Results Differences between patients who had amputation, limb-sparing surgery, or rotationplasty were consistently demonstrated by the FMA. Patients with limb sparing femur surgery performed better than those patients with an above the knee amputation but similarly to a small number of rotationplasty patients. Several of the more conventional self-report measures were shown to not have the discriminative capabilities of the FMA in these cohorts. Conclusion In adolescents with lower-extremity bone sarcoma, it may be advantageous to consider the use of a combination of outcome measures, including the FMA, for objective functional mobility assessment along with the TESS for a subjective measure of disability and the SF-36v.2 for a quality-of-life measure. Pediatr Blood Cancer 2007;49:964–969. © 2006 Wiley-Liss, Inc.
- Published
- 2006
33. Case Reports: Polymethylmethacrylate Lung Embolus after Limb-salvage Surgery of the Distal Femur
- Author
-
Najat C. Daw, Bhaskar N. Rao, Michael N Neel, M. Beth McCarville, and Jesse J. Jenkins
- Subjects
Male ,musculoskeletal diseases ,medicine.medical_specialty ,Biopsy ,medicine.medical_treatment ,Chest pain ,Diagnosis, Differential ,Fatal Outcome ,Embolus ,medicine ,Humans ,Polymethyl Methacrylate ,Orthopedics and Sports Medicine ,Femur ,Thoracotomy ,Embolization ,Child ,Osteosarcoma ,Lung ,business.industry ,Femoral Neoplasms ,Bone Cements ,General Medicine ,Limb Salvage ,medicine.disease ,Surgery ,Pulmonary embolism ,medicine.anatomical_structure ,Orthopedic surgery ,Radiology ,medicine.symptom ,Pulmonary Embolism ,Tomography, X-Ray Computed ,business - Abstract
Limb-salvage surgery for malignant tumors frequently involves reconstruction with an endoprosthesis anchored to bone by using third-generation cementing techniques. A 10-year-old boy with osteosarcoma had a pulmonary embolus caused by polymethylmethacrylate after having limb-salvage surgery that used high-pressure cementing techniques. He experienced transient postoperative chest pain, and a new wedge-shaped radiodense pulmonary lesion appeared on a computed tomography scan of the chest. A thoracotomy for resection of suspected metastatic osteosarcoma revealed a pulmonary infarct caused by cement embolization. Awareness of this potential complication should prompt investigation of possible pulmonary embolism and may prevent unnecessary thoracotomy.
- Published
- 2006
34. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas
- Author
-
Wayne L. Furman, Fariba Navid, Sheri L. Spunt, Alberto S. Pappo, Alvida M. Cain, Catherine A. Billups, Bhaskar N. Rao, Thomas E. Merchant, Victor M. Santana, and Gregory A. Hale
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Vincristine ,Adolescent ,Cyclophosphamide ,medicine.medical_treatment ,Bone Neoplasms ,Sarcoma, Ewing ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Rhabdomyosarcoma ,Mucositis ,Humans ,Medicine ,Ifosfamide ,Child ,Etoposide ,Chemotherapy ,business.industry ,Infant ,Sarcoma ,medicine.disease ,Combined Modality Therapy ,Surgery ,Doxorubicin ,Female ,business ,medicine.drug - Abstract
BACKGROUND Intensified chemotherapy may improve the outcome of patients with high-risk pediatric sarcomas. Vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide are highly effective against pediatric sarcomas. The authors investigated the feasibility of administering these agents concomitantly within a defined period. METHODS In the prospective high-risk sarcoma (HIRISA) Phase II trial HIRISA1, pediatric patients with high-risk sarcomas received 3 cycles of intensive vincristine, ifosfamide, etoposide, cyclophosphamide, and doxorubicin (VACIE) before radiotherapy and/or surgery began at Week 9 with concurrent vincristine, cyclophosphamide, and doxorubicin (Week 9) and vincristine and ifosfamide (Week 12). Three additional cycles of VACIE were then given. After delayed hematologic recovery in the first 11 patients, the protocol was modified (HIRISA2) to delay local control therapy until after 5 cycles of VACIE (to be completed within 18 weeks). Patients who responded to the protocols were eligible for myeloablative consolidation with autologous stem cell support. RESULTS Eleven of 24 patients (median age, 14.9 years) had Ewing sarcoma family of tumors, 9 patients had rhabdomyosarcoma, and 4 patients had unresectable desmoplastic small round cell tumors. Seven of 13 patients on HIRISA2, but none of 11 patients on HIRISA1, completed therapy within the specified time. Reversible Grade 4 myelosuppression was the most common toxicity. Major nonhematologic toxic effects were mucositis, nutritional impairment, hypotension, and peripheral neuropathy. Three patients died of toxicity. The 5-year survival and 5-year event-free survival estimates both were 45.8% ± 11.2%. CONCLUSIONS The feasibility of administering intensive chemotherapy regimens like VACIE was dependent in part on the timing of local control therapy. This regimen was associated with significant toxicity. Cancer 2006. © 2006 American Cancer Society.
- Published
- 2006
35. Metastatic osteosarcoma
- Author
-
M. Beth McCarville, Alvida M. Cain, Carlos Rodriguez-Galindo, Catherine A. Billups, William H. Meyer, Bhaskar N. Rao, Najat C. Daw, Michael D. Neel, and Jesse J. Jenkins
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Ifosfamide ,business.industry ,medicine.disease ,Primary tumor ,Carboplatin ,Metastasis ,Surgery ,Clinical trial ,chemistry.chemical_compound ,chemistry ,Internal medicine ,medicine ,Osteosarcoma ,Methotrexate ,Sarcoma ,business ,medicine.drug - Abstract
BACKGROUND. The outcome of patients with metastatic osteosarcoma treated in two consecutive trials from 1986 to 1997 was analyzed to evaluate the efficacy of carboplatin-based multiagent chemotherapy and to identify prognostic factors. The initial study (OS-86) used ifosfamide, cisplatin, doxorubicin, and high-dose methotrexate, and the subsequent study (OS-91) used the same agents at similar doses, but carboplatin was substituted for cisplatin. METHODS. Twelve patients (median age, 15.1 yrs) were treated in OS-86 for osteosarcoma metastatic to the lung only (11 patients) or bone only (I patient), and 17 patients (median age, 15.1 yrs) were treated in OS-91 for osteosarcoma metastatic to the lung only (12 patients), bone only (2 patients), lung and bone (2 patients), or other site (1 patient). RESULTS. Patients with metastatic disease enrolled in OS-86 and those with metastatic disease enrolled in OS-91 did not differ in terms of demographic features, histologic subtype, site of primary tumor, or site of metastases. There was a difference in survival according to treatment protocol (P = 0.054). All survivors (four of whom were enrolled in OS-86 and one of whom was enrolled in OS-91) had lung metastases only. Five-year survival estimates for patients with lung metastases only were 45.5 ± 13.7% (OS-86) and 8.3 ± 5.6% (OS-91) (P = 0.084). Unilateral lung metastases (P = 0.006), no more than three lung nodules (P = 0.014), and surgical remission (P = 0.001) were associated with improved survival probability. CONCLUSIONS. The poor outcome of patients with metastatic osteosarcoma treated in OS-91 justifies the use of cisplatin with its associated toxicity in patients with high-risk disease.
- Published
- 2006
36. Predictors of outcome in children and adolescents with rhabdomyosarcoma of the trunk—the St Jude Children's Research Hospital experience
- Author
-
Bhaskar N. Rao, Sheri L. Spunt, Chan Hon Chui, Catherine A. Billups, and Alberto S. Pappo
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Tumor resection ,Disease ,Hospital experience ,Abdominal wall ,Rhabdomyosarcoma ,medicine ,Humans ,Child ,Survival analysis ,Neoplasm Staging ,Retrospective Studies ,business.industry ,Infant ,Retrospective cohort study ,General Medicine ,Thoracic Neoplasms ,Prognosis ,medicine.disease ,Survival Analysis ,Trunk ,Surgery ,medicine.anatomical_structure ,Abdominal Neoplasms ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Disease Progression ,Female ,Neoplasm Recurrence, Local ,business - Abstract
Purpose The aim of this study was to determine predictors of outcome in childhood truncal rhabdomyosarcoma. Methods Retrospective chart review evaluating the impact of demographic features, disease characteristics, and the extent and timing of surgical intervention on outcome was performed. Results Thirty-three patients with a median age of 8 years were identified. Most had advanced Intergroup Rhabdomyosarcoma Study group III (n = 13) or group IV (n = 9) disease. Primary site included 20 (61%) chest wall, 6 (21%) paraspinal, 5 (15%) periscapular, and 1 (3%) abdominal wall. Most tumors were embryonal (n = 21), larger than 5 cm (n = 27), and locally invasive (n = 13); 7 had positive nodes. Tumor size, nodal status, and gross total tumor resection (upfront or delayed) were significant predictors of event-free and overall survival. Tumors 5 cm or smaller were amenable to upfront surgical resection ( P = .007). In patients with tumors larger than 5 cm, resection at any time was associated with a 10-year overall survival 57% ± 13% compared with 8% ± 5% in those who had no surgery ( P = .003). Tumor recurrence was local in 44% of cases, and survival after local recurrence was rare (1 of 8). Conclusion Tumor size, nodal status, and gross total resection at any time are significant predictors of outcome in truncal rhabdomyosarcoma. Gross tumor excision should be the goal of surgical intervention in this disease.
- Published
- 2005
37. Phase II Trial of Neoadjuvant Vincristine, Ifosfamide, and Doxorubicin With Granulocyte Colony-Stimulating Factor Support in Children and Adolescents With Advanced-Stage Nonrhabdomyosarcomatous Soft Tissue Sarcomas: A Pediatric Oncology Group Study
- Author
-
Meenakshi Devidas, Jessee Jenkins, Charles B. Pratt, Mark C. Gebhardt, Alberto S. Pappo, Robert Marcus, Patrick R.M. Thomas, Holcombe E. Grier, and Bhaskar N. Rao
- Subjects
Cancer Research ,Vincristine ,Chemotherapy ,medicine.medical_specialty ,Ifosfamide ,business.industry ,medicine.medical_treatment ,Soft tissue sarcoma ,Urology ,medicine.disease ,Synovial sarcoma ,Surgery ,Oncology ,medicine ,Sarcoma ,business ,Neoadjuvant therapy ,Mesna ,medicine.drug - Abstract
Purpose To describe the response rate and survival of children and adolescents with unresected or metastatic nonrhabdomyosarcomatous soft tissue sarcomas (NRSTS) treated with vincristine, ifosfamide, and doxorubicin. Patients and Methods Between September 1996 and June 2000, 39 eligible patients received vincristine (1.5 mg/m2 weekly for 13 doses), ifosfamide (3 g/m2 daily for 3 days every 3 weeks for seven cycles), doxorubicin (30 mg/m2 daily for 2 days for six cycles), and mesna (750 mg/m2 for four doses after ifosfamide). Granulocyte colony-stimulating factor was administered daily (5 μg/kg) after each cycle of chemotherapy. Radiotherapy was administered from weeks 7 through 12. Results The median patient age at diagnosis was 11.7 years; the most common primary tumor site was lower extremity (36%); and synovial sarcoma was the predominant histology. More than three fourths of all tumors were 5 cm or greater at their largest diameters. The overall objective combined partial and complete response rate was 41% (95% CI, 25.7% to 56.7%). The estimated 3-year overall survival and progression-free survival rates (± standard deviation) for eligible patients were 59% ± 8.2% and 43.6% ± 7%, respectively. Patients with clinical group III disease had significantly better 3-year and progression-free survival rates compared with patients who presented with metastatic disease. Conclusion The vincristine, ifosfamide, and doxorubicin regimen was moderately active against pediatric NRSTS. Patients with synovial sarcoma had higher response rates than other patients, and patients with unresected disease had improved outcomes. Patients with metastatic disease continue to fare poorly, and newer approaches are indicated for these patients.
- Published
- 2005
38. Osteosarcoma of the pelvis in children and young adults: The St. Jude Children's Research Hospital experience
- Author
-
Bhaskar N. Rao, N B S Tamra Fortenberry, Carlos Rodriguez-Galindo, Najat C. Daw, Raya Saab, and Catherine A. Billups
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Metastasis ,medicine ,Humans ,Child ,Pelvis ,Pelvic Neoplasms ,Retrospective Studies ,Osteosarcoma ,business.industry ,Cancer ,Retrospective cohort study ,Prognosis ,medicine.disease ,Sacrum ,Surgery ,Radiation therapy ,Hemipelvectomy ,Treatment Outcome ,medicine.anatomical_structure ,Oncology ,Female ,Sarcoma ,business - Abstract
BACKGROUND Pelvic osteosarcomas are difficult to resect. The authors reviewed their institution's experience with patients who had such tumors to characterize the patients' clinical findings and to assess the impact of surgical resection on outcome. METHODS A review was conducted of the records from patients with pelvic osteosarcoma who were treated at the authors' institution between January, 1970 and March, 2004. RESULTS Among 442 patients with osteosarcoma, 19 patients (4%) had high-grade tumors arising in the pelvic bones, including the ilium in 15 patients, the pubis in 2 patients, and the sacrum in 2 patients. The median patient age at diagnosis was 16.8 years. Four tumors were secondary to radiation therapy. Five patients had metastases in the lung (n = 4 patients) or bone (n = 1 patient) at diagnosis. Ten tumors were chondroblastic. The median greatest tumor dimension for the 13 tumors with known size was 10 cm. Ten patients had unresectable pelvic tumors, and 9 patients underwent hemipelvectomy (2 internal and 7 external); complete resection with negative margins was achieved in 5 patients. Four patients survived, including one patient who survived with disease. Of the three patients who survived disease-free, one patient underwent complete resection, one patient underwent incomplete resection (nonviable tumor at the soft tissue margin) with a good response to chemotherapy, and one patient with a sacral tumor underwent radiotherapy only for local control. Of the 9 patients who underwent resection, 7 experienced disease recurrence (n = 5 patients) or progression (n = 2 patients) at distant sites and died. All patients with metastatic disease at diagnosis died. CONCLUSIONS Pelvic osteosarcomas often were large and unresectable. A high propensity for metastasis contributed to the poor outcome of patients with pelvic osteosarcoma. New therapeutic approaches are needed. Cancer 2005. © 2005 American Cancer Society.
- Published
- 2005
39. Minimally Invasive Surgery in Pediatric Cancer Patients
- Author
-
Thom E Lobe, Kurt P. Schropp, Andrew M. Davidoff, Stephen J. Shochat, Bhaskar N. Rao, and William W. Spurbeck
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,endocrine system diseases ,Postoperative Complications ,Surgical oncology ,Neoplasms ,otorhinolaryngologic diseases ,Thoracoscopy ,Humans ,Minimally Invasive Surgical Procedures ,Medicine ,Single institution ,Child ,Laparoscopy ,Retrospective Studies ,Laparotomy ,medicine.diagnostic_test ,business.industry ,General surgery ,Infant ,Pediatric cancer ,Surgery ,Treatment Outcome ,Oncology ,Child, Preschool ,Pediatric malignancy ,Invasive surgery ,Female ,business - Abstract
The specific use of minimally invasive surgery (MIS) in pediatric cancer patients is limited. We evaluated the 5-year experience at a single institution with MIS in children with malignancies.A retrospective review was undertaken of all MIS performed between November 1995 and October 2000.A total of 101 pediatric oncology patients underwent 113 MIS procedures-64 laparoscopic (57%) and 49 thoracoscopic (43%)-during this period. Laparoscopy was performed for diagnostic purposes in 27 cases (42%) and was successful in 25 (93%) cases. Laparoscopic tumor resection was performed in seven cases (11%). Thirty additional laparoscopic procedures (47%) were attempted for complications of the malignancy or its treatment. Four of these cases were converted to open laparotomies. Indications for thoracoscopy included the evaluation of a mediastinal mass (n = 7) or biopsy or resection of pulmonary lesions (metastatic, n = 31; infectious, n = 9). Fourteen cases (29%) had to be converted to open thoracotomy procedures, generally because of the inability to localize a lesion. The other 35 procedures were successful. The overall complication rate was 5%. No trocar site recurrences or infections were observed.We conclude that MIS in pediatric cancer patients is a safe and effective diagnostic modality. The role of MIS for primary tumor resection remains to be defined.
- Published
- 2004
40. Outcome after local recurrence of osteosarcoma
- Author
-
Nirali Shah, Bhaskar N. Rao, Carlos Rodriguez-Galindo, Najat C. Daw, Michael N. Neel, M. Beth McCarville, and Catherine A. Billups
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Bone Neoplasms ,Risk Assessment ,Amputation, Surgical ,Disease-Free Survival ,Cohort Studies ,Age Distribution ,medicine ,Humans ,Sex Distribution ,Child ,Survival analysis ,Neoplasm Staging ,Probability ,Retrospective Studies ,Osteosarcoma ,Chemotherapy ,business.industry ,Cancer ,Retrospective cohort study ,Hospitals, Pediatric ,medicine.disease ,Survival Analysis ,Surgery ,Oncology ,El Niño ,Amputation ,Chemotherapy, Adjuvant ,Child, Preschool ,Female ,Sarcoma ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies ,Cohort study - Abstract
BACKGROUND Despite improvements in therapy for osteosarcoma, approximately 4–10% of patients experience a local recurrence and have a poor prognosis. METHODS The authors analyzed prognostic factors for survival in 26 patients with a local recurrence of osteosarcoma who were treated between 1970 and 2000. RESULTS The initial surgical procedure was amputation in 20 patients (76.9%) and limb salvage in 6 patients (23.1%). The median time from the diagnosis of osteosarcoma to local recurrence was 1.2 years (range, 1.2 months–6.1 years). Eleven patients (42.3%) developed an isolated local recurrence and 15 patients (57.7%) developed local and distant recurrence. The 5-year estimate of postrecurrence survival (PRS) (± 1 standard error) for the 26 patients was 19.2% ± 7.7%. Recurrence ≥ 2 years from the time of diagnosis was found to predict a better outcome (5-year PRS of 50.0% ± 20.4%) compared with earlier recurrence (10.0% ± 5.5%) (P = 0.037). Patients with negative margins after initial surgery were found to have improved survival (5-year PRS of 33.3% ± 13.6%) compared with patients with positive margins (7.1% ± 4.9%) (P = 0.015). Patients who underwent complete surgical resection at the time of recurrence were found to have a better PRS (5-year PRS of 41.7% ± 14.2%) compared with patients who did not undergo surgery (0% ± 0%) (P < 0.001). CONCLUSIONS The prognosis for patients after local recurrence of osteosarcoma is poor. Complete surgical resection at the time of recurrence is essential for survival. Positive margins at the time of initial surgical resection and early recurrence appear to be poor prognostic factors. Cancer 2004. © 2004 American Cancer Society.
- Published
- 2004
41. Pediatric gastrointestinal stromal tumors and leiomyosarcoma
- Author
-
Bhaskar N. Rao, Najat C. Daw, Alberto S. Pappo, Monica S. Cypriano, and Jesse J. Jenkins
- Subjects
Leiomyosarcoma ,Cancer Research ,medicine.medical_specialty ,biology ,GiST ,CD117 ,business.industry ,medicine.medical_treatment ,Cancer ,medicine.disease ,digestive system diseases ,Surgery ,Radiation therapy ,Imatinib mesylate ,Oncology ,medicine ,biology.protein ,Sarcoma ,Radiology ,Stromal tumor ,business ,neoplasms - Abstract
BACKGROUND With the introduction of molecularly targeted therapy for gastrointestinal stromal tumors (GISTs), it became important to distinguish GISTs from leiomyosarcomas (LMSs). The authors sought to characterize the clinicopathologic features of these tumors in pediatric patients. METHODS The authors reviewed the medical records of 11 patients for whom GIST or LMS was diagnosed between March 1962 and July 2002 at St. Jude Children's Research Hospital and reclassified the tumors according to current histologic and immunophenotypic criteria. The authors also reviewed the literature pertaining to pediatric GISTs and LMSs. RESULTS Seven patients had GISTs, and four had LMS. The median age of the patients at diagnosis was 11.5 years. At diagnosis, metastases were present in one patient with GISTs and in another with LMS. Unlike the focal distribution of CD117 (KIT) in LMS, diffuse and strong immunostaining was observed in GISTs. Only GISTs expressed CD34. Six patients underwent complete resection (four with GISTs and two with LMS), four patients underwent incomplete resection (three with GISTs and one with LMS), and one patient (with LMS) underwent a biopsy only. Radiotherapy or chemotherapy was used to treat one patient with GISTs and three patients with LMS. One patient with a high-risk GIST (largest dimension of 32 cm and high mitotic count) was treated with adjuvant imatinib mesylate outside the preferred setting of a clinical trial, due to concerns regarding the high risk of tumor recurrence. Four patients with GISTs and two with LMS survived median disease-free a median of 10.4 years and 4.3 years after diagnosis, respectively. Tumors in all but one survivor were completely resected. CONCLUSIONS KIT staining helped to distinguish GISTs from LMSs. Surgery was the treatment of choice for both entities, and tumor resectability was a key prognostic factor. Cancer 2004. © 2004 American Cancer Society.
- Published
- 2004
42. Local control in childhood extremity sarcomas: Salvaging limbs and sparing function
- Author
-
Bhaskar N. Rao and Carlos Rodriguez-Galindo
- Subjects
Cancer Research ,medicine.medical_specialty ,Bone Neoplasms ,Sarcoma, Ewing ,Sarcoma ewing ,Rhabdomyosarcoma ,medicine ,Humans ,Child ,Neoplasm Staging ,Leg ,Osteosarcoma ,business.industry ,Soft tissue ,Sarcoma ,Prognosis ,medicine.disease ,Combined Modality Therapy ,Surgery ,Oncology ,Pediatrics, Perinatology and Child Health ,Arm ,Radiotherapy, Adjuvant ,Neoplasm staging ,business - Published
- 2003
43. Early Multicenter Experience With a Noninvasive Expandable Prosthesis
- Author
-
Ross M Wilkins, Michael D. Neel, Cynthia M. Kelly, and Bhaskar N. Rao
- Subjects
Male ,Reoperation ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Radiography ,Bone Neoplasms ,Prosthesis Design ,Prosthesis ,Amputation, Surgical ,Bone Lengthening ,Activities of Daily Living ,medicine ,Humans ,Orthopedics and Sports Medicine ,Femur ,Range of Motion, Articular ,Arthroplasty, Replacement, Knee ,Child ,Salvage Therapy ,Osteosarcoma ,Tibia ,business.industry ,Femoral Neoplasms ,Age Factors ,General Medicine ,medicine.disease ,Primary tumor ,Arthroplasty ,Leg Length Inequality ,Prosthesis Failure ,Surgery ,Treatment Outcome ,Amputation ,Orthopedic surgery ,Female ,business ,Range of motion ,Follow-Up Studies - Abstract
A noninvasive expandable prosthesis for skeletally immature children after limb salvage surgery has been developed. Between 1998 and 2001, 18 Phenix prostheses were implanted in 15 pediatric patients who had been diagnosed and treated for osteosarcoma about the knee. Of the 15 original prostheses, 10 were implanted at the time of primary tumor resection and five were revisions from an endoprosthetic modular knee system. Sixty expansions of the 18 prostheses were done, with all but two done as outpatient procedures. An average 8.5 mm was obtained per lengthening (range, 1-30 mm). The average followup was 21.5 months (range, 12-33 months) and the latest Musculoskeletal Tumor Society functional scores averaged 90%. Eight revisions were required for stem fracture or loosening. There was one amputation because of a postoperative arterial thrombosis. The principle of the Phenix prosthesis involves storage of energy in a spring compressed by a locking system. Lengthening is achieved via exposure to an electromagnetic field that allows controlled release of the spring. This is a unique expandable custom prosthesis that offers many benefits in maintaining limb length equality in growing patients. Although the early experience is promising, additional data are required regarding the long-term structural integrity of the prosthesis. We are optimistic that this technology will prove beneficial, not only for patients with malignant bone tumors but in applications requiring serial limb length equalizations or for spinal deformities.
- Published
- 2003
44. Benefit of surgical resection of invasive pulmonary aspergillosis in pediatric patients undergoing treatment for malignancies and immunodeficiency syndromes
- Author
-
Stephen J. Shochat, F. A. Hoffer, Andrea Hayes-Jordan, Andrew M. Davidoff, Jerry L. Shenep, Bhaskar N. Rao, Catherine A. Billups, Kenneth W. Gow, and Kurt P. Schropp
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,Opportunistic Infections ,Malignancy ,Aspergillosis ,Immunodeficiency Syndrome ,Immunocompromised Host ,Myelogenous ,medicine ,Humans ,Child ,Survival analysis ,Bone Marrow Transplantation ,Leukemia ,Lung Diseases, Fungal ,business.industry ,Mortality rate ,Respiratory disease ,Immunologic Deficiency Syndromes ,Infant ,General Medicine ,medicine.disease ,Survival Analysis ,Surgery ,Treatment Outcome ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Female ,business - Abstract
The aim of this study was to evaluate the outcome of children undergoing treatment for malignancy and immunodeficiency syndromes in whom invasive pulmonary aspergillosis (IPA) developed.The authors reviewed the medical records of all patients treated at their institution from January 1990 to August 1999 for culture-proven pulmonary aspergillus infection.Among the 43 patients studied, the median age at the time of diagnosis of IPA was 13.1 years. The most common primary diagnoses were acute myelogenous leukemia (n = 18) and acute lymphoblastic leukemia (n = 14); 27 patients (63%) had received a bone marrow transplant (BMT). Of the 18 patients who underwent surgical intervention for IPA, 14 (78%) had one operation, whereas the remaining 4 patients had 2. The 4 patients alive at the time this report was written had undergone surgical intervention 2, 10, 23, and 44 months previously respectively. Surgical resection of the involved lung parenchyma was significantly prognostic for survival (P.001). Other factors that influenced outcome were the extent of pulmonary invasion, steroid use, and the timing of bone marrow transplantation (BMT) in regard to the diagnosis of IPA.The overall mortality rate of children treated for malignancies and immunodeficiency syndromes in who IPA develops remains high, and antifungal therapy alone may not be curative. Surgical resection may provide a small but possibly the only chance for survival. Therefore, we would advocate for resection of all involved tissue, even if it requires reoperation.
- Published
- 2003
45. Malignant fibrous histiocytoma and other fibrohistiocytic tumors in pediatric patients
- Author
-
Hazem Mahmoud, Matthew J. Krasin, Najat C. Daw, Bhaskar N. Rao, Catherine A. Billups, Alberto S. Pappo, and Jesse J. Jenkins
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Soft Tissue Neoplasms ,medicine ,Humans ,Neoplasm Metastasis ,Child ,Survival rate ,Histiocytoma, Benign Fibrous ,Angiomatoid fibrous histiocytoma ,business.industry ,Plexiform fibrohistiocytic tumor ,Wide local excision ,Infant ,Cancer ,Prognosis ,medicine.disease ,Primary tumor ,Surgery ,Survival Rate ,Oncology ,Child, Preschool ,Localized disease ,Female ,Sarcoma ,business ,Follow-Up Studies - Abstract
BACKGROUND Malignant fibrous histiocytoma (MFH) is a controversial entity. In the current study, the authors reviewed their institutional experience with these tumors to characterize their clinical features in pediatric patients and assess the impact of surgical resection on outcome. METHODS The records of the 28 patients who were diagnosed with MFH or MFH variants of soft tissue between January 1971 and December 2000 were reviewed and the tumors were reclassified according to the World Health Organization guidelines. RESULTS Seventeen patients had MFH; 10 patients had angiomatoid fibrous histiocytoma (FH), and 1 patient had a plexiform fibrohistiocytic tumor. The median age of patients at the time of diagnosis was 7.3 years. The most common primary tumor site was the extremity (n = 14). Metastatic disease (to the lung) was present in only three patients, each of whom had MFH. Of the 17 MFH tumors, 13 were high grade, 8 were invasive, and 6 measured > 5 cm. All angiomatoid FH tumors and the plexiform fibrohistiocytic tumor were noninvasive, and 10 measured ≤ 5 cm. Surgical treatment was comprised of wide local excision with clear margins (n = 18), amputation (n = 3), excision with positive or indeterminate surgical margins (n = 4), partial resection (n = 2), or biopsy only (n = 1). Primary reexcision was performed for 21 patients. The 5-year survival and event-free survival (EFS) estimates for patients with MFH were 76.5% ± 11.2% and 70.6% ± 12.1%, respectively; the 5-year survival and EFS estimates were 100% ± 0% for patients with angiomatoid FH or plexiform fibrohistiocytic tumor. Compared with partial resection or excision, wide local excision or amputation was found to have a positive impact on the probability of EFS in patients with localized disease (P = 0.008). All four patients with metastatic or unresectable MFH had died by the time of last follow-up. CONCLUSIONS MFH should be distinguished from angiomatoid FH and plexiform fibrohistiocytic tumors, both of which are less aggressive. Wide local excision is the treatment of choice, regardless of the histology or grade of the tumor. Patients with metastatic or unresectable MFH appear to have a poor outcome and would benefit from more effective therapies. Cancer 2003;97:2839–47. © 2003 American Cancer Society. DOI 10.1002/cncr.11384
- Published
- 2003
46. Painful Limp in a 10-Year-Old Boy
- Author
-
Jesse J. Jenkins, Bhaskar N. Rao, Najat C. Daw, Sue C. Kaste, Michael D. Neel, and Patrick C. Toy
- Subjects
Male ,medicine.medical_specialty ,Knee Joint ,Limp ,business.industry ,Synovial Membrane ,Diagnostico diferencial ,General Medicine ,Magnetic Resonance Imaging ,Lower limb ,Surgery ,Diagnosis, Differential ,Radiography ,medicine ,Humans ,Orthopedics and Sports Medicine ,Hemangioma, Capillary ,medicine.symptom ,Child ,business - Published
- 2003
47. Magnetic Resonance Imaging After Incomplete Resection of Soft Tissue Sarcoma
- Author
-
Tami J. Shidler, Michael M. Neel, Sue C. Kaste, Laurie Conley, Bhaskar N. Rao, and Ashley Hill
- Subjects
Male ,medicine.medical_specialty ,Neoplasm, Residual ,Adolescent ,Soft Tissue Neoplasms ,Sensitivity and Specificity ,Resection ,Sarcoma, Synovial ,medicine ,Humans ,Orthopedics and Sports Medicine ,Child ,medicine.diagnostic_test ,business.industry ,Soft tissue sarcoma ,Infant ,Sarcoma ,Magnetic resonance imaging ,General Medicine ,medicine.disease ,Incomplete Resection ,Magnetic Resonance Imaging ,Predictive value ,Synovial sarcoma ,Child, Preschool ,Female ,Surgery ,Radiology ,business - Abstract
Review of magnetic resonance imaging was compared with the pathologic review of reexcision specimens from 24 pediatric patients who had initial incomplete resection for soft tissue sarcoma to determine the accuracy of magnetic resonance imaging in detecting residual tumor. The median age of patients was 12.8 years. The most common diagnosis was synovial sarcoma (eight of 24 patients; 30%). Magnetic resonance imaging detected residual tumor in eight patients and no tumor in eight patients; the images of eight patients were indeterminate. Pathologic examination showed residual tumor in 14 of 24 (58%) specimens obtained in reexcision. For two of the eight patients (25%) for whom imaging had detected no tumor, microscopic examination detected residual tumor; for one of the eight patients for whom imaging had detected tumor, microscopic examination detected no tumor. Five of the eight patients (63%) for whom the results of imaging studies were indeterminate had residual tumor on microscopic evaluation. The sensitivity of magnetic resonance imaging for detecting residual tumor was 78%, the specificity was 86%, the positive predictive value was 0.78, and the negative predictive value was 0.86. Decisions regarding the need for additional resection should not be based on magnetic resonance imaging alone.
- Published
- 2002
48. Survival after recurrence of Ewing Tumors
- Author
-
Catherine A. Billups, Victor M. Santana, Alberto S. Pappo, Thomas E. Merchant, Bhaskar N. Rao, Carlos Rodriguez-Galindo, Charles B. Pratt, and Larry E. Kun
- Subjects
Adult ,Male ,Cancer Research ,Poor prognosis ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Bone Neoplasms ,Sarcoma, Ewing ,Hospital experience ,Risk Factors ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,In patient ,Radical surgery ,Child ,Retrospective Studies ,Salvage Therapy ,Chemotherapy ,Radiotherapy ,business.industry ,Cancer ,Prognosis ,medicine.disease ,Surgery ,Survival Rate ,Treatment Outcome ,Oncology ,El Niño ,Child, Preschool ,Female ,Treatment factors ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies - Abstract
BACKGROUND Despite improved therapies, 30–40% of patients with Ewing tumors (ET) experience recurrence and have a poor prognosis. The authors analyzed factors prognostic of survival in patients with recurrent ET. METHODS The authors assessed the relation between postrecurrence survival (PRS) and demographic, disease, and treatment factors in 71 patients who experienced recurrent ET after treatment on one of three consecutive institutional protocols. RESULTS Thirty-four patients (47.9%) had distant recurrence, 25 patients (35.2%) had local recurrence, and 12 patients (16.9%) had both distant and local recurrence at a median of 1.7 years after diagnosis. The probability of 5-year PRS (± 1 standard error) was 17.7% ± 4.5%. Recurrence ≥ 2 years after diagnosis predicted a significantly better outcome (5-year PRS, 34.9% ± 8.5%) compared with earlier recurrence (5.0% ± 2.8%; P < 0.001). Patients who had both local and distant recurrence fared worse (5-year PRS, 12.5% ± 8.3%) compared with patients who had local recurrence alone (21.7% ± 7.8%) or distant recurrence alone (17.6 ± 6.1%). Among patients with local recurrence alone, those who underwent salvage with radical surgery had significantly higher 5-year PRS estimates (31.4% ± 11.6%) compared with the other patients (9.1% ± 6.1%; P = 0.023). Pulmonary irradiation significantly improved the outcomes of patients with isolated pulmonary recurrence (5-year PRS estimate, 30.3% ± 12.5% vs. 16.7% ± 10.8%, respectively; P = 0.018). CONCLUSIONS Although outcomes are generally poor after patients experience recurrence of ET, certain patient groups differ appreciably in their likelihood of survival. Patients who experience recurrence ≥ 2 years after diagnosis and patients who have local recurrence that can be treated with radical surgery and intensive chemotherapy have the most favorable outcomes. Cancer 2002;94:561–9. © 2002 American Cancer Society.
- Published
- 2002
49. Bilateral internal hemipelvectomy for osteosarcoma in a pediatric patient previously treated for rhabdomyosarcoma
- Author
-
M.D. Neel, Bhaskar N. Rao, Mary Beth McCarville, Israel Fernandez-Pineda, Rachel C. Brennan, and Sheri L. Spunt
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Bone Neoplasms ,Hemipelvectomies ,Resection ,Hemipelvectomy ,Rhabdomyosarcoma ,Medicine ,Humans ,Orthopedics and Sports Medicine ,Child ,Pelvic Bones ,Internal hemipelvectomy ,Pelvis ,Radiation-induced tumors ,Osteosarcoma ,business.industry ,Neoplasms, Second Primary ,medicine.disease ,Surgery ,Pediatric patient ,medicine.anatomical_structure ,Urinary Bladder Neoplasms ,Female ,business ,Previously treated - Abstract
The surgical treatment of malignant bone tumors involving the pelvis represents a great challenge in terms of local control. Internal hemipelvectomy is a major surgical procedure that involves the resection of the entire hemipelvis or of a portion of the hemipelvis with preservation of the ipsilateral extremity. The need for a bilateral internal hemipelvectomy is an extraordinary situation. We describe the case of an 11-year-old girl with a primary diagnosis of rhabdomyosarcoma of the bladder at the age of two years who subsequently developed a right pelvis osteosarcoma at the age of six years and a left pelvis osteosarcoma at the age of nine years. She ultimately underwent sequential bilateral internal hemipelvectomies and she postoperatively ambulates without an assist device.
- Published
- 2014
50. Recurrent osteosarcoma with a single pulmonary metastasis: a multi-institutional review
- Author
-
Carlos Rodriguez-Galindo, Bhaskar N. Rao, Paul A. Meyers, Winston W. Huh, Norman Jaffe, Alexander J. Chou, Catherine A. Billups, and Najat C. Daw
- Subjects
Oncology ,Male ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,recurrence ,Adolescent ,nodule ,medicine.medical_treatment ,Bone Neoplasms ,Disease ,thoracotomy ,chemotherapy ,Disease-Free Survival ,lung ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Thoracotomy ,Young adult ,Child ,030304 developmental biology ,Retrospective Studies ,0303 health sciences ,Chemotherapy ,Osteosarcoma ,Lung ,solitary ,business.industry ,Retrospective cohort study ,medicine.disease ,Prognosis ,3. Good health ,medicine.anatomical_structure ,Treatment Outcome ,030220 oncology & carcinogenesis ,Clinical Study ,Female ,Metastasectomy ,Neoplasm Recurrence, Local ,business ,metastasectomy - Abstract
Background: Late relapse and solitary lesion are positive prognostic factors in recurrent osteosarcoma. Methods: We reviewed the records of 39 patients treated at three major centres for recurrent osteosarcoma with a single pulmonary metastasis more than 1 year after diagnosis. We analysed their outcomes with respect to clinical factors and treatment with chemotherapy. Results: Median age at diagnosis was 14.6 years. Relapse occurred at a median of 2.5 years (range, 1.2–8.2 years) after initial diagnosis. At relapse, all patients were treated by metastasectomy; 12 (31%) patients also received chemotherapy. There was no difference in time to recurrence or nodule size between the patients who received or did not receive chemotherapy at relapse. Sixteen patients had no subsequent recurrence, 13 of whom survive without evidence of disease. The 5-year and 10-year estimates of post-relapse event-free survival (PREFS) were 33.0±7.5% and 33.0±9.6%, respectively, and of post-relapse survival (PRS) 56.8±8.6% and 53.0±11.0%, respectively. There was a trend for nodules
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.